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The opioid crisis in the United States was declared a public health emergency due to
escalating and untoward human, financial, and systemic consequences and effects on the
nation. Opioid use disorder (OUD) comprising opioid abuse and dependence is devastating
because of its associated chronic relapsing nature, overutilization of healthcare services,
rising morbidity and mortality rates, and high cost of care. Efforts to address this have not
made significant positive impacts. It is thus imperative to reassess the influence of factors
associated with OUD.
This study answered the question, what patient-, hospital-, and state-level policy
factors were associated with prevalence of diagnosing and treating OUD in U.S. emergency
departments (ED), since the ED which were usually first point-of-contact with the healthcare
system by patients with OUD witnessed significantly increased visits related to nonmedical
use of opioids.
A retrospective secondary data analysis of the cross-sectional Nationwide Emergency
Department Sample of patients 12 years and older from January 1 to December 31, 2016;

ASAM state reports; SAMHSA Office of Policy, Planning and Innovation State Medicaid
coverage reports; and KFF report on opioid epidemic was performed. Outcome variable was
prevalence of diagnosing and treating OUD in the ED. Primary predictor variable was OUD
condition, and covariates included, patient characteristics – primary payer, annual median
income, patient location, and ED event; hospital characteristics – control/ownership, region,
and designation; and state-level policy characteristics – medication-assisted treatment (MAT)
policy, MAT medication coverage, Medicaid expansion, and Medicaid section 1115
behavioral health waiver statuses. Descriptive statistics was reported for all variables.
Pearson’s chi-squared was test used to determine statistically significant differences between
opioid abuse and opioid dependence diagnosis. Hierarchical linear regression model (HLM)
was used to estimate association between outcome and predictor variables.
In total, 32,680,232 ED visits in 953 hospitals across 35 states and District of
Columbia which when generalized to the entire United States amounted to 144,842,742 visits
to the ED in 4,639 hospitals across the 50 states including the District of Columbia were
analyzed. The total number of opioid-related incidents to the ED was 1,623,490. The overall
prevalence of any opioid-related incident was 1.12% while overall prevalence of diagnosis
and treatment of uncomplicated OUD in U.S. ED was 0.5%. Significant regional disparities
existed in state-level opioid policies, prevalence of uncomplicated OUD and other
characteristics influencing treatment of OUD in U.S. ED. Opioid dependence patients
(55.6%) were preponderantly of upper-lower income class, micropolitan residents, covered
by Medicare; admitted to same hospital they presented, attended to largely in privatelyowned not-for-profit ED, in micropolitan areas, and in Southern and Western U.S. Opioid

abuse patients (44.4%) were predominantly of lower-lower income status, metropolitan
dwellers, Medicaid covered; presented commonly to privately-owned not-for-profit ED, in
metropolitan locations, and in Northeastern and Midwestern U.S. Combined, patient and
hospital-level policy characteristics accounted for 25.4% (R2=0.254, Adj. R2=0.254, F
change (3,734618)=31937.906, p<0.0001) of variance in prevalence of treating OUD in ED.
Patient characteristics only accounted for 15.6% (R2=0.156, Adj. R2=0.156,
F(5,734621)=27245.686, p<0.0001) and hospital characteristics only for 9.7% (R2
change=0.097, F(3,734618)=31937.906, p<0.0001) of the variance. Proportion of variance
accounted for by each predictor variable was, control/ownership of hospital (9.67%), patient
location (6.35%), annual median income (1.44%), hospital designation (1.21%), OUD
diagnosis (0.20%), primary payer (0.04%), region of hospital (0.02%), and ED event
(0.008%).
Patient and hospital level characteristics significantly influenced prevalence of
treating OUD in U.S. ED. Hospital-level characteristics contributed more that patient-level
characteristics. A socioecological approach, which ensures an integrated and holistic method,
is required to understand factors influencing OUD with the view to developing innovative
policies and programs that can positively and significantly address the opioid crisis.
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BACKGROUND
Introduction
This dissertation will determine the prevalence of emergency care of opioid use disorder
in the United States population 12 years and older with a view to guiding drug policy and
program implementation.
The devastating effects of opioids in developed and developing nations is no longer news.
What may be news is the context in which the problem is framed which invariably affects
perceptions of the scope of the problem and how it is addressed subsequently. The President of
the United States, under federal law declared the opioid crisis in America as a national public
health emergency on October 26, 2017 (The White House, 2017).
Current research on opioids focuses on prescribing and dispensing practices
(Jayawardhana et al, 2018; Cochran et al, 2017; Dowell et al, 2016); treatment of specific
conditions such as chronic pain, back disorders, arthritis, inflammatory bowel disease (Hayes et
al, 2018; Cohen-Mekelburg et al,2018); prevention of opioid overdoses (Peglow et al, 2018;
Huhn et al, 2018; McGinty et al, 2018; Lynch et al, 2017); treatment of substance use disorders
especially opioid overdoses (Zhu et al, 2018; Vipler et al, 2018; Garland et al, 2018; BrinkleyRubinstein et al, 2018; Borodovsky et al, 2018; Heslin et al, 2017; Mosher et al, 2017);
adherence/non-adherence to treatment (Lo-Ciganic et al, 2018); prevalence of specific conditions
(e.g. obesity, HIV, mental health disorders) among opioid use disorder (OUD) populations (Hu
et al, 2018; Shrestha et al, ;2018; Cochran et al, 2017); substance use disorders including opioids
(Serdarevic et al, 2018; Hawk et al, 2018); cost of providing treatment (Chang et al, 2018;
Burgos et al, 2018; Xie et al, 2014; Chandwani et al, 2013); and molecular and pharmacogenetic
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basis of treating substance use disorders including OUD (Fang etal, 2018; Schroeder et al, 2018,
Crist et al, 2018; Laudenbach et al, 2018).
Furthermore, recent opioid research has focused on community-based populations (Serdarevic et
al, 2018; Cochran et al, 2017), specific populations such as children and adolescents 12-17 years
old (Borodovsky et al, 2018; Levy et al., 2016; Wu et al., 2016; Hadland et al., 2016; Xie et al,
2014; Muhuri et al., 2013, SAMHSA, 2013a), women (Hayes et al, 2018; Serdarevic et al, 2018),
pregnant women (Jayawardhana et al, 2018; Peglow et al, 2018), incarcerated individuals
(Brinkley-Rubinstein et al, 2018), individuals enrolled in clinical trials (Hu et al, 2018); and
privately insured individuals (Sun et al, 2017).
The sites of these studies have been mainly inpatient-based (Zhu et al, 2018; Peglow et
al, 2018; Cohen-Mekelburg et al, 2018; Heslin et al, 2017; Mosher et al, 2017; Gaither et al,
2016), a combination of inpatient-based and emergency department visits (Peterson et al, 2018;
Tedesco et al, 2017; Wu et al., 2016) or ambulatory clinics only (Peglow et al, 2018; Wu et al.,
2016). Few have focused on patients with OUD visiting the emergency department only (Hawk
et al, 2018; Wu et al., 2016; Xie et al, 2014; Chandwani et al, 2013).
This research fills an important gap in providing current estimates of the prevalence of
diagnosing and treating OUD in emergency departments (ED) in the United States. The
implications of this research include guiding policymaking, resource allocation, program
planning and implementation regarding management of OUD in the ED (Burgos et al, 2018;
Friedmann et al, 2017; Molfenter et al, 2017; Ford et al, 2017).
Why study disease prevalence?
Estimating burden of disease specifically prevalence may potentially influence health
policy development and implementation regionally and globally (Degenhardt et al, 2014a).
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How does prevalence estimations influence policy?
Prevalence of disease influence policy by driving change and leading to meaningful
differences in health outcomes (Aldrich et al, 2015).
Literature Review
In this review of the literature, the timeline of the opioid crisis in the United States is
highlighted, opioid crisis as a public health emergency is discussed, the opioid crisis is evaluated
using the quadruple aim framework and the significance of opioid use disorder is emphasized.
Advocacy for better treatment of pain in the United States started in 1991 (Tsang et al.,
2008). This resulted in introduction of opioid analgesics (pain relievers) to manage both acute
and chronic pain. Opioids are a class of drugs consisting of Schedule II analgesics such as
codeine, oxycodone, hydrocodone, morphine, and legally prescribed fentanyl; and the Schedule I
drug – heroin – considered illicit. The achievement of pain relieving effects of opioids are
through stimulation of neurotransmitter production in the central nervous system and
gastrointestinal tract (National Institute on Drug Abuse, 2015). When taken as prescribed by
healthcare providers and over a short period, opioid analgesics are essentially safe. However,
because of the added euphoric effects, opioids may not be taken as prescribed, taken in quantities
lager than prescribed or taken without being prescribed (National Institute on Drug Abuse,
2015). Notwithstanding legally prescribed or illicitly obtained, opioids readily result in abuse
leading to opioid use disorder (OUD) such as dependency and addiction. Consequences of
iatrogenic or recreational long-term use of opioids include physical and/or psychological
dependence, overdose, and death (National Institute on Drug Abuse, 2015). Specifically,
problematic uses of opioids are categorized and defined as (1) Misuse – “opioid use contrary to
the directed or prescribed pattern of use, regardless of the presence or absence of harm or
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adverse effects”. (2) Abuse – “intentional use of the opioid for a nonmedical purpose, such as
euphoria or altering one’s state of consciousness”. (3) Addiction – “pattern of continued use with
experience of, or demonstrated potential for, harm” which may include inability to control use of
the drug, habitual drug use, constant drug use in the face of harm, and insatiable craving
(Naliboff et al., 2011; Smith et al., 2013; Butler, 2013; Sullivan, 2013; Vowles et al., 2015).
There is controversy over using the term “addiction” or “dependence” (O’Brien et al., 2006;
Regier et al, 2013). However, in the American Psychiatric Association Diagnostic and Statistical
Manual of Mental Disorders, fifth Edition (DSM-5) Classification, “dependence” is the preferred
term. According to the DSM-5 classification, the two disorders, opioid abuse and opioid
dependence, have now been combined into a single term – Opioid Use Disorder (Hartney &
Gans, 2008; Regier et al, 2013).
An unintended consequence of the advocacy efforts and subsequent escalation in pain
treatment of the early 1990s was an increase over four times of prescription opioid induced
overdose mortality between 1999 and 2018 (Seth et al., 2018). A proportion of opioid users
began their dependence on the drug following legal prescription of opioids by healthcare
providers (Schoenfeld et al, 2017). Furthermore, attributed to use of prescription opioids was the
initiation of drug abuse in 80% of heroin users (Muhuri et al., 2013). Over 116 million
individuals are living with chronic pain in the United States (Seth et al., 2018). Concerning
chronic pain treatment, between 21% and 29% percent of individuals on prescription opioids
ultimately misuse their medication with 8% to 12% becoming addicted (Vowles et al., 2015).
Consequently, the United States is currently experiencing a significant opioid misuse crisis
(Trasolini et al, 2018).
Opioid Crisis in America
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Timeline of opioid analgesic use and opioid crisis
Pre 1800 to 1800 – Prior to 1800, clinicians viewed pain as part of human existence and
experience. It was considered a result of aging (Meldrum, 2003a). As such, not regulating use of
cocaine and opioids in this era resulted in pervasive marketing and prescription for various
illnesses from toothache to diarrhea (Clarke et al, 2016).
1801 to 1979 – During the 19th century, opioids were used as standard treatment for acute
and recurrent pain. In 1804, Friedrich Wilhelm Sertürner produced morphine from crude opium
(Schmitz, 1985). By the 1820s, Germany had commenced industrial production of morphine
followed a decade later by the United States. In 1855, Alexander Wood invented the technique of
using a hypodermic syringe and fine bore needle to deliver morphine subcutaneously to pain
sites. The convenience of this mode of ensuring pain relieve may have heralded overuse of
morphine for analgesia (Howard-Jones, 1947). Furthermore, non-regulation and easily available
over the counter formulations of opium and alcohol-based preparations as pills, liquids and
powders made self-medication convenient. This trend continued into the 1870s during which
physicians started observing the “repeated indulgence inducing bodily and mental prostration
and mental perversion” associated with “the morphine habit” or “narcomania” of using morphine
(Kerr, 1894). Germany’s Bayer Company started marketing diacetylated morphine pills for
treatment of cough under the trade name of “Heroin” in 1898. This diacetylated morphine
introduced as less habit-forming was an alternative to morphine. However, by 1910, diacetylated
morphine pills were being crushed into powder and inhaled for concentrated high by the young
working-class in the United States. The rising trend of morphine (heroin) addiction due to legal
and illicit use resulted in overwhelming support of the Harrison Narcotic Control Act of 1914.
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A consequence of this Act was “opiophobia”, where both physicians and patients avoided
prescribing and using opioid analgesics respectively. (Meldrum, 2003a; Meldrum, 2003b; Jones
et al., 2018). Thus, by the 1920s, patients with unexplained pain were categorized as deluded,
malingers or abusers looking for a “heroin fix” while into the 1950s, patients with cancer were
encouraged to self-wean off opioids (Schiffrin, 1956). Opiophobia continued into the second half
of the twentieth century (Meldrum, 2003a; Jones et al., 2018). Therefore, under-treatment of
pain, another consequence, led to advocacy to bring awareness to this issue especially following
a 1973 Annals of Internal Medicine publication by Richard Marks and Edward Sachar (Marks &
Sachar, 1973).
1980 to 1989 – Generally, in the 1980s, several physicians were fearful of prescribing
opioids in spite of an extensively cited article suggesting opioid-induced addiction was rare with
opioids taken for short-term pain (Porter & Jick, 1980). Specifically, John Morgan in 1985 in the
United States and Michael Zenz and Anne Willweber-Strumpf in 1992 in Europe stressed the
issue of less reliance on opioid analgesics and resultant under-treatment of pain. This was due to
physicians’ conflict arising from their desire to relieve adequately the pain of patients and their
fear of inducing addiction in these patients (Morgan, 1985; Zenz & Willweber-Strumpf, 1993).
In spite of education, clinical guidelines, and advocacy to change the perceptions, attitudes, and
believes of physicians towards prescribing opioids for pain management, practice had not change
(National Institutes of Health, 1986; American Pain Society, 1987, WHO, 1986, 1996; Carr &
Jacox, 1997). Thus, due to the attendant problem of underassessment and under-treatment of
pain, opinion leaders and experts in the field called for improved assessment, robust and more
vigorous treatment methods to address the problem of inadequate pain management including the
use of opioids (Max, 1990, Baker, 2017).
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1990 to 1999 – Following the work of Morgan and Zenz and Willweber-Strumpf, the
clear call for a change in the strategy for assessment and management of pain intensified in the
1990s. The American Pain Society through its then president, Dr. Mitchell Max was at the
forefront of these efforts. He wrote an editorial in Annals of Internal Medicine criticizing the lack
of improvement in assessment and treatment of pain over the preceding two decades (Max,
1990). In addition, education, advocacy, and clinical guidelines in the prior decade from
Ubaker.S. Agency for Health Care Policy and Research, American Pain Society, and World
Health Organization had not worked (National Institutes of Health, 1986; American Pain
Society, 1987, WHO, 1986, 1996; Carr & Jacox, 1997). Reasons proffered for this failure
included patients not informing their healthcare providers about their pain, nurses’ inability to
adjust pain medication doses, and physicians’ reluctance to prescribe opioids. In taking a new
approach to pain management, Dr. Max stressed then conventional wisdom that “therapeutic use
of opiate analgesics rarely results in addiction”. He thus recommended (1) making pain “visible”.
(2) Giving practitioners “bedside” tools for change to guide physicians and nurses to initiate and
modify analgesic treatments. (3) Assuring patients a place in the “communications loop”. (4)
Increasing clinician accountability by developing “quality assurance guidelines”, improving care
systems, and assessing patient satisfaction. (5) Facilitating innovation and exchange of ideas. (6)
Working with narcotics control authorities to encourage therapeutic opiate use.
Consequently, in response to greater awareness of pain levels of patients and more therapeutic
use of opioids, and prior to acknowledgement of the opioid crisis, healthcare providers were
motivated to treat pain generously with opioid analgesics (Max, 1990; Baker, 2017). The
resultant effect was pressure to prescribe opioid analgesics every time pain was reported
(Trasolini et al, 2018). As such, pain was promoted as the “fifth vital sign” and an “enemy that
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needed to be eradicated” (Baker, 2017). For instance, in 1999, California’s legislature voted for
an act necessitating that facilities record pain levels together with routine vital sign
measurements (Escutia, 1999).
In 1995, the Food and Drug Administration approved OxyContin® (Oxycodone) for treatment of
pain. Misleadingly and aggressively marketed as a non-addicting opioid analgesic, OxyContin
quickly developed into a widely prescribed pain reliever. Consequently, there was a 153% rise in
opioid analgesics prescribing between 1990 and 1999 from 76 to 116 million prescriptions
respectively (Baker, 2017). In many ways, the discovery that OxyContin® was an opioid with a
high risk for addiction and dependence may have driven the second wave of the opioid crisis
(Van Zee, 2009).
2000 to 2009 – The Joint Commission in collaboration with the University of WisconsinMadison School of Medicine and experts nationwide started to develop its first pain standards in
1997 and completed it in 2000. The Joint Commission initiative followed the advocacy by
American Pain Society for novel quality assurance standards for acute and cancer pain, and as a
result of the overall paucity of knowledge regarding pain management, and misunderstandings
concerning tolerance and addiction to drugs (American Pain Society, 1987; Institute of Medicine,
1987; Campbell, 1995). Part of the requirements of the Joint Commission’s standards was that all
healthcare organizations were to assess systematically and quantitatively every patient for pain
(Morone & Weiner, 2013; Barker, 2017). Furthermore, the United States Congress declared a
“Decade on Pain Control and Research,” from 2001 to 2011. Following this, there was increase
in opioid analgesics prescribing. Equally, due to public health research efforts, there were
increasing reports of misuse, addiction, and deaths due to opioid-related overdoses (Interagency
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Pain Research Coordinating Committee, 2015). All these coincided with when OxyContin® had
become a leading drug of abuse in the United States in 2004 (Van Zee, 2009).
2010 to present – In 2011, the prescription of opioid analgesics had risen to 219 million
prescriptions – a 288% and 189% rise from 1990 and 1999 levels respectively. It was 255
million prescriptions in 2012 (335%, 219%, and 116% rise from 1990, 1999, and 2011 levels
respectively) (Baker, 2017; Centers for Disease Control and Prevention, 2018b). By 2015, over
33,000 Americans had died from opioid overdose due to prescription opioids, heroin, and
illegally manufactured synthetic opioid – Fentanyl (Centers for Disease Control and
Prevention/National Center for Health Statistics, 2018). Reported in 2015 in the United States
were approximately 2 million cases of substance use disorders associated with prescription
opioids and 591,000 cases of heroin use disorder not mutually exclusive from the former (Center
for Behavioral Health Statistics and Quality, 2016).
The third wave of the opioid crisis ushered in in 2013 was due to synthetic opioids such as
fentanyl. By 2016, mortality related to illegally manufactured fentanyl and not diverted medical
fentanyl and associated drugs was over 20,000. Illegally manufactured fentanyl was being used
to adulterate or as a replacement for other drugs of abuse (Ciccarone, 2017; Dismukes, 2018; Liu
et al., 2018).
In 2016, Centers for Disease Control and Prevention (CDC) provided comprehensive guidelines
for best practices regarding prescribing opioids for non-cancer related chronic pain, in an effort
to curb risks associated with prescribing opioid analgesics and to maximize available benefits
accruable from different pain treatment alternatives (Dowell et al., 2016). Some of these
recommendations include using non-opioid treatment regimens as the first line of approach to
treating non-cancer related chronic pain; and using opioid analgesics only following cautious
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pain control assessment and constant evaluations for their continued indication (Dowell et al.,
2016). Figure 1 shows a timeline summary of opioid analgesic use and opioid crisis in America.
Figure 1. Timeline of Opioid Analgesic Use and Opioid Crisis
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Opioid Crisis as a Public Health Emergency
The opioid crisis in the United State was declared a public health emergency (PHE) on
October 26, 2017 by Eric D. Hargan, then Acting Secretary of Health and Human Services
(Hargan, 2017; Health and Human Services, 2017). This declaration made at the behest of the
President and following necessary consultation with public health officials was extended through
April 24, 2018 (Health and Human Services, 2017; Haffajee et al., 2018). The declaration of the
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opioid crisis in America as a public health emergency was necessary due to the escalating and
untoward consequences and impacts of the crisis on the nation (Haffajee et al., 2014). Prior to
the declaration, over 190 deaths per day in the United Sates were due to drug overdoses. Of
these, over 130 deaths per day were the result of opioid overdoses (Centers for Disease Control
and Prevention/National Center for Health Statistics, 2018). In addition, between 1999 and 2017,
there was a 256% increase in age-adjusted rate of drug overdose mortality from 6.1 to 21.7 per
100,000 (Hedegaard et al., 2018). Furthermore, in fiscal year 2017 ending September 30,
approximately $900 million had been invested on training, education, treatment and recovery,
and other support services for opioid-related conditions by the United States’ Department of
Health and Human Services (Health and Human Services, 2017). As such, declaring the crisis a
public health emergency (PHE) was intended to, allow the federal government take legitimate
actions devoid of legislative bureaucracy to address the opioid crisis, permit use of new funds or
repurposing of existing funds to deal with the crisis, expedite ad hoc subject-matter expert
appointments to proffer solutions, ensure collaboration with agencies such as the Drug
Enforcement Agency to increase telemedicine access for opioid dependence treatment for
specific patients requiring such services, and to ensure that HIV/AIDS programs have
flexibilities that included managing associated opioid-related conditions (Haffajee et al., 2014;
Health and Human Services, 2017).
Opioid Crisis in context of the Quadruple Aim
The Quadruple Aim is a modification to and expansion of the Triple Aim Framework of
healthcare improvement by inclusion of a fourth dimension – Improving provider experience of
care. The justification for including this fourth dimension is based on the argument that attaining
a truly effective health system performing at optimal levels requires a satisfied, motivated, and

14

engaged healthcare workforce devoid of burnout (Bodenheimer & Sinsky, 2014; Sikka et al.,
2015; West, 2016). Triple Aim on the other hand, is a framework describing an approach to
enhancing performance of health systems. The Triple Aim framework posits that improving
performance of health systems through new systems designs must consider three interdependent
dimensions (Triple Aim): 1) Improving care experience of patients; 2) Improving population
health; and 3) Reducing per capita healthcare cost. The Institute for Healthcare Improvement
(IHI) developed the Triple Aim framework (Institute of Healthcare Improvement, n.d; Berwick
et al., 2008).
Opioid crisis and individual experience of care
An approach to evaluating the opioid crisis is to view it at the individual level as a
person-specific problem, which influences individual experience of care. Prolonged use and/or
use at higher doses of prescription opioids potentially increases risk of opioid use disorder,
overdose, and death. Some of the individual patient-level person-specific factors shown to drive
the opioid crisis include: previous history of substance abuse and mental health status (Ives et al.
2006; Sullivan et al. 2010; Fischer et al. 2012); economic circumstances of individuals including
employment and income (Case and Deaton, 2015; 2017). Over 30% of individuals in the United
States suffer from acute or chronic pain (Johannes et al., 2010; Simon, 2012). The high
prevalence of chronic pain coupled with its frequently debilitating effects underscores the reason
for opioid analgesics being the most frequently prescribed category of medications in the United
States (Centers for Disease Control and Prevention, 2012). Given the rising rates of patients
progressing from use of opioid analgesics for treatment of pain to misuse and subsequent
dependence, advocates are calling for more controlled prescribing of opioids. However, the
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opioid crisis is a multi-faceted problem of which curbing prescribing rates is just one part
(Patient Engagement HIT, 2018).
Concerning chronic pain, prevalence is increasing in United States adults. Studies have
estimated that the prevalence of chronic pain in U.S adults ranges between 11% and 40%
(National Institute of Health, 2016). In 2012, 11.2% of adults in U.S experienced chronic pain
(Nahin, 2015) which increased to 20.4% in 2016 (Dahlhamer et al., 2016). Living with chronic
pain can rapidly develop into problems of quality of life. Since the pain affects the experience of
patients during daily activities, it can limit their participation in daily routines including school,
work, and social activities. However, long-tern treatment with opioids predisposes these patients
to a higher risk misuse, dependence and progression to heroin addiction (Volkow et al., 2016).
Adequately treating both acute (such as post-surgical pain) and chronic pain (such as
non-cancer related chronic pain) is critical to a positive individual patient experience of care –
including quality of care and satisfaction with care. Healthcare providers however find
themselves put in a position of conflict between satisfactorily relieving patients’ pain, improving
their experience of care, quality of life, and preventing misuse of and dependence on opioid
analgesics. Thus, reconciliation between the current opioid crisis, treatment of pain, and ensuring
patient satisfaction with care received puts healthcare providers in a difficult position (Morgan,
1985; Zenz & Willweber-Strumpf, 1993; Patient Engagement HIT, 2018). Furthermore, efforts
at addressing the opioid crisis by limiting supply may be depriving patients who rightfully need
opioids from receiving life-sustaining treatment and for those on long-term treatment with
opioids from legitimately filling their prescriptions (Nicholson, 2018; Schultz, 2018). This may
ultimately result in lack of improved experience of care.
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As such, a vital point to addressing the opioid crisis requires understanding the role of
opioids in care of patients with pain. Treatment for pain in some patients may require opioid
analgesics leading to improved satisfaction with care while others may benefit from alternative
paint management options. On the other hand, patients need to understand how to use opioid
analgesics responsibly while appreciating the risks associated with taking these medications.
Therefore, patient and provider education is important in efforts to address the opioid crisis
(Patient Engagement HIT, 2018).
Opioid crisis and population health
Another approach of framing the opioid crisis is as a population health problem. This
potentially broadens the scope of the problem beyond the individual. This population health
approach involves confronting root causes, trans-sectoral collaborations, eradicating inequalities
in access to treatment, and tackling and decreasing racial biases and stigma (Gourevitch, 2018)
compared to focusing more on individual experience of care or lack thereof. This approach
ensures multi-pronged efforts to reversing the trend on the crisis and subsequently improving the
health of populations. This in other words would require a systems approach to the opioid crisis
((Martin et al., 2016); Martin & Laderman, 2016).
There are demographic, socioeconomic, and healthcare-related characteristics associated
with the opioid crisis. Demographic characteristic includes: (i) Race – predominantly Caucasian
and/or African American. Socioeconomic characteristics include: (i) Poverty. (ii)
Unemployment. (iii) Low educational attainment. Healthcare-related characteristics include: (i)
Uninsured. (ii) High healthcare services utilization such as those suffering with chronic pain.
(Ghertner & Groves, 2018; Karamouzian & Kerr, 2018; Keyes et al., 2014; Muhuri et al., 2013;
Cicero et al., 2014; Vowles et al., 2015; Carlson et al., 2016; National Institute on Drug Abuse,
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2018c; Guy et al., 2017; Webster et al., 2009; McDonald et al., 2012; Wennberg, 2011;
McDonald & Carlson, 2014). There are however, four different types of patient sub-populations
associated with the opioid crisis. These distinct but interdependent sub-populations include the:
(1) naïve patient; (2) high-dose chronic use patient; (3) opioid-dependent, seeking within
healthcare patient; and (4) opioid-dependent, seeking outside of healthcare patient (Martin et al.,
2016). Based on the risk factors above, approximately 21% to 29% of patients with chronic pain
prescribed opioid eventually misuse the prescribed opioids. Eight percent to 12% ultimately
develop opioid use disorder while about 4% to 6% of those misusing the prescribed opioids
switch to using heroin (Muhuri et al., 2013; Cicero et al., 2014; Vowles et al., 2015; Carlson et
al., 2016; National Institute on Drug Abuse, 2018c).
To adequately address the opioid crisis and subsequently improve the health of
populations, policy makers and health systems should make decisions and allocate resources that
specifically target these populations.
Opioid crisis and per capita cost of care
Per capita cost – Regarding the opioid crisis, per capita cost of care refers to the average
cost of caring for opioid use disorder per person or average cost of healthcare for opioid use
disorder per member of the population (Institute of Healthcare Improvement, n.d; Berwick et al.,
2008). Total cost – The total cost of the opioid crisis to the United States is immense. This total
cost includes: (1) tangible cost – such as healthcare, criminal justice, lost productivity cost; and
(2) intangible cost – comprising cost to quality of life, emotional cost, and cost of pain/suffering
endured (Brill & Ganz, 2018). In 2015, the total cost of the opioid crisis including mortality,
healthcare, criminal justice and lost productivity costs to the United States economy was 2.8% of
GDP and estimated to be $504 billion. This total cost of the opioid crisis is a combination of; (1)
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mortality cost – consisting of value of statistical lives lost due to opioid overdoses – of $431.7
billion (85.7%) and (2) non-mortality cost – consisting of average cost of non-fatal consequences
of opioid use disorder – of $72.3 billion (14.3%) (Council of Economic Advisers, 2017). This
total cost is over six to forty-eight times more than previously estimated cost of the crisis to the
US economy (Birnbaum et al., 2006, Birnbaum et al., 2011, Florence et al., 2016). It is important
to note that other prior estimated costs focused on estimating the cost of prescription opioids
only. However, the current total cost of $504 billion is six to forty-eight times higher because it
includes the cost of both prescription and illicit opioids; fatalities due to opioid overdoses have
increased significantly; and value of lives lost were fully accounted for in the $504 billion
estimate. In addition, there are geographical variations to the distribution of this cost that need to
be accounted for at the federal, state and local levels when policies are being enacted to address
the opioid crisis (Council of Economic Advisers, 2017; Brill & Ganz, 2018).
In 2015 dollars, while total healthcare expenditures per capita by state of residence in the
United States revealed a national average of $8,054.55, total health care expenditures per capita
for states with the top five highest total per capita cost of the opioid crisis were all above the
national average and within the top 20 highest health care expenditures per capita for that year.
Specifically, West Virginia was 12th at 118% ($9,473.23) of national average; Washington, D.C.
1st at 148% ($11,958.18); New Hampshire 9th at 119% ($9,600.38); Ohio 17th at 108%
($8,722.34); and Maryland 19th at 106% ($8,612.21). For states with the top five lowest total per
capita cost of opioid crisis, Iowa, Montana, and Nebraska had total health care expenditures per
capita by state of residence above the national average while those for Mississippi and Texas
were below national average. Specifically, Iowa was 25th at 101% ($8,209.73) of national
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average; Mississippi 34th at 95% ($7,655.08); Texas 45th at 86% ($7,006.31); Montana 24th at
102% ($8,230.76); and Nebraska 20th at 104% ($8,421.98).
State-level total and non-mortality per capita cost of the opioid crisis are spatially
distributed. In 2015, states with the top five highest total per capita cost of the opioid crisis
included West Virginia – $4,378; Washington, D.C. – $3,657; New Hampshire – $3,640; Ohio –
$3,385; and Maryland – $3,337. These states mostly in the Appalachian region are all in the
eastern United States except for Ohio, which is in the Midwest. States with the top five lowest
total per capita cost included Iowa – $705; Mississippi – $703; Texas – $653; Montana – $596;
and Nebraska – $394. These states are in the Midwestern and southern United States. (Brill &
Ganz, 2018). Similarly, states with the top five highest non-mortality per capita cost of the opioid
crisis were Washington, D.C. – $493; New Hampshire – $360; Connecticut – $358; Washington
– $331; and New York – $320. These states are all in the eastern United States except for
Washington, which is in the west. States with the top five lowest non-mortality per capita cost
were Texas – $144; Arkansas – $143; Mississippi – $138; Nebraska – $126; and Iowa – $118.
These states are in the Midwestern and southern United States. (Brill & Ganz, 2018).
Regarding states with the top five highest and lowest non-mortality per capita cost of the
opioid crisis, health care expenditure per capita by state of residence not already mentioned were
Connecticut 6th at 122% ($9,870.70) of national average, Washington 31st at 98% ($7,922.39),
New York 9th at 121% ($9,789.61); and Arkansas 38th at 92% ($7,416.39) respectively in 2015.
It is important to note here that health care expenditure per capita (also known as health spending
per capita) is “spending for all privately and publicly funded personal health care services and
products (hospital care, physician services, nursing home care, prescription drugs, and so on) by
state of residence (aggregate spending divided by population)”. Where included hospital costs
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represent total net revenue comprised of gross charges less contractual adjustments, bad debts,
and charity care. Excluded from this total health care expenditure per capita are insurance
program administration, research, and construction-related costs (Kaiser Family Foundation,
2017b).
Also, of significance is the percentage of total health care expenditure per capita by state
of residence that both the total and non-mortality per capita cost of the opioid crisis constitute
respectively. Concerning states with the top five highest total per capita cost of the opioid crisis,
West Virginia’s opioid crisis comprises about 46%; Washington, D.C. 30%; New Hampshire
37%; Ohio 38%; and Maryland 38% of the total health care expenditure per capita by state of
residence respectively. For states with the top five lowest total per capita cost of opioid crisis,
Iowa’s opioid crisis constitutes about 8%; Mississippi 9%; Texas 9%; Montana 7%; and
Nebraska 4% of the total health care expenditure per capita by state of residence respectively.
In relation to states with the top five highest non-mortality per capita cost of the opioid
crisis, Washington, D.C.’s opioid crisis consist of approximately 4%; New Hampshire 3%;
Connecticut 3%; Washington 4%; and New York 3% of the total health care expenditure per
capita by state of residence respectively. For states with the lowest non-mortality per capita cost
of the opioid crisis, Texas was 2%; Arkansas 1%; Mississippi 1%; Nebraska 1%; and Iowa 1%
of the total health care expenditure per capita by state of residence respectively. Table 1 shows
the total health care expenditure per capita by state of residence, total per capita cost of the
opioid crisis (as a percentage of the total health care expenditure per capita by state of residence),
and non-mortality per capita cost of the opioid crisis (as a percentage of the total health care
expenditure per capita by state of residence) of the top five states in the United States.
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Table 1. Total Health Care Expenditure per Capita by State of Residence, Total per Capita Cost
and Non-Mortality per Capita Cost of Opioid Crisis of Top Five States in United States.
Top Five States
Total Health
Care
Expenditure
per Capita
by State
(a)
Value
($)
11,958.18
9,600.38
9,473.23
8,722.34
8,612.21

State
Washington D.C.
New Hampshire
West Virginia
Ohio
Maryland

Total
per Capita
Cost of
Opioid Crisis
(b)
%
([b/a]*100)
30.58
37.91
46.21
38.81
38.75

Non-Mortality
per Capita
Cost of
Opioid
Crisis
(c)
%
([c/a]*100)
4.12
3.75
3.78
3.79
3.72

State
Washington D.C.
New Hampshire
Connecticut
Washington
New York

The spatial variations in the opioid crisis and per capita cost of care in the United States
can be attributed to geography and socioeconomic factors (Keyes et al., 2014; Ghertner &
Groves, 2018; Karamouzian & Kerr, 2018). (1) Rural-urban geographic divide – where as noted
above, rural areas including most of the Appalachian region, parts of the West and the Midwest,
and New England, are disproportionately more affected by the opioid crisis compared to more
urban areas; (2) socioeconomic factors – specifically high unemployment and high poverty have
been shown to be associated with the opioid crisis (Ghertner & Groves, 2018). However, there
are exceptions to these observed association in which urban areas experience and some
economically disadvantaged areas do not experience the opioid crisis (Ghertner & Groves,
2018). These geographic and socioeconomic factors attributable to the opioid crisis have resulted
in varying; (1) Opioid prescribing and dispensing practices in the United States in which more
opioids are prescribed and dispensed in the Appalachian region, Southern, and Western states of
the United States (McDonald et al., 2012). (2) Internal migration patterns in which there is
movement of people between and within states and counties in search of economic prosperity
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and better healthcare services (Finkelstein et al., 2018). Furthermore, counties within states in the
Appalachian region, Southern, and Western United States tend to have more opioids prescribed
and dispensed. This is due to those counties having greater (i) resident population size (ii) white
non-Hispanic or African American (iii) economically disadvantaged, uninsured (iv) urban
classified dwelling population and (v) number of opioid prescribing providers (Wennberg, 2011;
McDonald et al., 2012; McDonald & Carlson, 2014). In addition, other factors such as political
affiliations, higher healthcare utilization, greater income disparities, and lower educational
attainment predispose these counties to prescribing and dispensing more opioids (Webster et al.,
2009; Goodwin et al., 2018; Guy et al., 2017).
Opioid crisis and provider experience of care
The quantity of opioid analgesics prescribed grew from 76 million prescriptions in 1990
to 116 million in 1999 to 255 million in 2012 and declined to 191 million in 2017 – the lowest in
over 10 years (Baker, 2017, Centers for Disease Control and Prevention, 2018b). However, in
spite of the overall rate of opioid analgesics prescribing rate in United States climaxing and
leveling off from 2010 to 2012 and decreasing since 2012, the quantity of opioids in morphine
milligram equivalents (MME) prescribed per person is still estimated at three times higher than it
was in 1999 (Centers for Disease Control and Prevention, 2017). This may have contributed in
part to the rising overall opioid-related deaths in the nation. Such that between 1999 and 2017,
approximately 218,000 deaths were reported in United States due to overdoses connected to
prescription opioids – a fivefold increase from 1999 to 2017 (WONDER, 2016). In addition, in
1999 and 2017, age-adjusted prescription opioid overdose mortality rates were 4,030 and 40,051
per 100,000 population respectively. This represents an estimated 10-fold increase is deaths due
to prescription opioids between 1999 and 2017 (Kaiser Family Foundation, 2018). Furthermore,
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in 2017, 46 deaths/day were attributed to prescription opioid overdoses accounting for over 35%
of all deaths related to opioid overdoses in that year (Scholl et al., 2018; Centers for Disease
Control and Prevention, 2018a).
Annual prescribing rates between 2006 and 2017 declined by over 19% with most of the
decline occurring from 2012 to 2017. In addition, prescribing rates of high-dose opioids has been
reducing since 2008 (Centers for Disease Control and Prevention, 2018a). All indicative of
cautious prescribing practices on the part of healthcare providers. However, not all healthcare
provider experiences of caring for individuals with opioid use disorder and opioid related drug
overdoses during the opioid crisis can be explained by adherence to best prescribing practices
only.
The experiences of healthcare providers caring for patients during the opioid crisis may
be influenced by certain factors. These include: (1) General overutilization of healthcare services
by individuals with substance use disorders (Walley et al., 2011; National Drug Intelligence
Center, 2011; Neighbors et al., 2013). (2) Repeated presentations at emergency departments and
readmissions to hospital of patients with opioid use disorder related conditions and opioid related
drug overdoses (Walley et al., 2011; National Drug Intelligence Center, 2011; Neighbors et al.,
2013). (3) Disproportionately high costs of healthcare incurred by patients with substance use
disorders including opioids (Walley et al., 2011; National Drug Intelligence Center, 2011;
Neighbors et al., 2013). (4) Underutilization or lack of use of substance use disorder-specific
interventions during inpatient admissions and at discharge (Knudsen et al., 2011; Knudsen &
Roman, 2012; Rosenthal et al., 2016; Donroe et al., 2016; McCarty et al., 2018).
Other plausible reasons related to the aforementioned include: (Ia) Associated regulations
and other treatment policies of patients with opioid use disorder related conditions and opioid
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related drug overdoses such as certification to dispense opioid drugs in the treatment of OUD
(CFR Title 42: Part 8: Subparts A through C). (Ib) Policies influencing opioid prescribing
practices (National Academies of Sciences, Engineering, and Medicine, 2017). (Ic) Additional
provider requirement to report pain and OUD data (National Academies of Sciences,
Engineering, and Medicine, 2017). (IIa) Healthcare provider biases such as fears related to
deception and manipulation by patients with opioid use disorder when presenting with or
reporting pain. (IIIa) Challenges associated to using agonist and antagonist medication such as,
patients and families explicitly requesting nondrug treatment, persistently expecting abstinence
as only appropriate outcome of treatment, resistance of healthcare staff to use of medications,
and medication cost. (IIIb) Lack of providers capable of prescribing required medications on
staff in many addiction treatment centers (Knudsen et al., 2011). (IV) Barriers related to routine
usage of extended-release naltrexone such as, difficulty ordering and administering the
medication, policies of health plans demanding prior authorization and review of utilization,
requirements of first failing at use of other treatment options, need for patients being free of
opioids the prior 7 to 10 days before injection, lack of care continuity by physicians, and cultures
that are resistant use of medication (Alanis-Hirsch et al., 2016).
All of these factors may result in healthcare provider dissatisfaction and burnout, which
adversely affects their experience of caring for patients with opioid use disorder related
conditions, and opioid related drug overdoses. This may ultimately lead to poor patient
experience of care including dissatisfaction and poor quality of care, poor population health
outcomes, and increased per capita cost of care (Bodenheimer & Sinsky, 2014).
Why is Opioid Use Disorder (OUD) important?
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Opioids – The estimated cost of the opioid crisis the United States between 2001 and
2017 exceeded $1.0 trillion and is projected to rise to $1.5 trillion by 2020 (Altarum, 2018).
Evidence shows that prescription opioids, not heroin, are the first opioids frequently abused
(Cicero et al, 2014). Approximately 67% of primary heroin users also use prescription opioids
(Rosenblum et al, 2007). Use of heroin and heroin-related mortality in the United States have
been on the rise since 2000 (Rudd et al, 2016).
Opioid Use Disorder (OUD) – OUD is a chronic relapsing condition involving frequent
misuse of prescription opioids, diversion and use of opioids, or use of heroin acquired illegally.
OUD is usually associated with considerably high rates of morbidity and mortality (Strain et al,
2015). Opioid use disorder, according to the DSM-V combines two disorders, namely; Opioid
Dependence and Opioid Abuse. OUD encompasses use of a wide range of illegal and prescribed
drugs of the opioid class (Hartney & Gans, 2018; Regier et al, 2013). Adverse events – such as
overdosing, abuse, dependence, and death – from using prescription opioids in the United States
have risen over the last 20 years (Chang et al, 2018). Opioid abusers have greater odds of visiting
the emergency departments, physician outpatient clinics; longer inpatient stays compared to nonabusers of opioids (Meyer et al, 2014).
Identifying individuals with OUD particularly in the ED can be challenging. This is
partly because there are no existing clinical guidelines for such tasks (Duber et al., 2018).
Clinically, individuals with OUD may present to the ED with somatic symptoms and signs such
as headaches and pain involving the joints, back, neck, chest or abdomen, elevated heart rate and
blood pressure; and psychological symptoms like agitation, panic attacks, and restlessness
(Braden et al., 2010; Kampman & Jarvis, 2015; Duber et al., 2018). Several different tools have
been developed for identifying patients or individuals with OUD (Duber et al., 2018). The
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similarities between these tools are that they accurately and reliably identify patients with OUD
while being easy to administer and integrate into providers’ existing workflows (Johnson et al.,
2013; Duber et al., 2018).
Prevalence of opioid use disorder
Approximately 12 million individuals 12 years and older misused prescription opioids in
the United States in 2016 (Reinhart et al, 2018). Over 130 people are estimated to die per day
from opioid-related overdoses (Centers for Disease Control and Prevention/National Center for
Health Statistics, 2018). According to the National Survey on Drug Use and Health, an estimated
total of 7.7 million, 7.4 million, and 7.6 million people 12 years and older suffered from OUD in
the 12 months preceding the survey in 2015, 2016, and 2017 respectively (SAMHSA – Center
for Behavioral Health Statistics and Quality, 2017, 2018). In addition, results from the National
Survey on Drug Use and Health revealed that in the 12 months prior to the survey, 2.1 million
people 12 years and older were first time misusers of prescription opioids. (SAMHSA – Center
for Behavioral Health Statistics and Quality, 2018). In 2015 or the most recent year, there was
significant state-level variability in OUD diagnosed in healthcare settings; aggregated data
revealed an estimated 10-fold difference in diagnosed OUD prevalence between South Dakota
(least impacted state at 1.32 per 1,000) and Vermont (most impacted state at 12.56 per 1,000)
(Davenport & Matthews, 2018).
Economic burden of opioid use disorder
Prescription abuse costs society $55 billion each year, with $20 billion in emergency
department and inpatient care alone (Fuehrlein et al, 2017). Approximately 75% treatment costs
for alcohol & other drug use disorder (DUD) including OUD is publicly funded alone (Mark et
al, 2005). Treatment expenditure for substance use disorder including OUD in the United States
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increased from $9 billion in 1986 to $21 billion in 2003 to $24 billion in 2009 and $31 billion in
2014 (Mark et al., 2007; SAMHSA, 2013b; SAMHSA, 2014). This amount is projected to
increase to about $42 billion in 2020 (SAMHSA, 2014).
Importance of opioid use disorder prevalence and cost in adolescents and young adults
Significant increases in opioid prescribing across all age groups have been observed in
recent years with parents more likely to share opioids with their children and/or diversion of
parents’ opioid pain relievers by children thus predisposing to OUD (Binswanger & Glanz,
2015). The most commonly initiated drugs of abuse among children, adolescents, and young
adults are opioids (SAMHSA, 2010). Adolescents (12-17 year old) and young adults (18-25 year
old) presenting to primary care with OUD and overdoses has been on the rise in the last 15 years
(Saloner et al., 2017). Misuse and abuse of prescription opioids in individuals 12-17 years old
and 18-25 years old more than doubled between 1991 and 2012 (SAMHSA, 1993, 2013a). An
estimated 5.4% of 12-17 year olds and 10% of 18-25 year olds reported nonmedical use of
prescription opioids (Binswanger & Glanz, 2015). In addition, 16.1% of 12-17 year olds and
20.9% of 18-25 year olds were at-risk of initiation of heroin use in the past year following prior
nonmedical opioid pain reliever use between 2002 and 2011 (Muhuri et al., 2013). The
proportion of admissions into substance abuse treatment facilities due to opioid use in
individuals 12 years and older increased from 18% in 2004 to 30% in 2014 (SAMHSA, 2014,
2017). There has been a six-fold increase of unintentional opioid poisonings in youth in the last
10 years (Binswanger & Glanz, 2015). In spite of expanded access to medications, on average
only 11.1% of 13 to 17 year olds received Buprenorphine and Naltrexone for OUD between
2001 and 2014 (Hadland et al., 2017). Disparities based on age, gender, and race/ethnicity exist
for OUD treatment among 13 to 25 year olds (Hadland et al., 2017; Feder et al., 2017). In
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addition, other characteristics such as; census region, insurance status, annual income, patient
location, hospital designation/location, treatment setting (e.g. ED, inpatient, and outpatient), and
disposition have been shown to influence prevalence and cost of OUD treatment (Wu et al.,
2016; Peterson et al., 2018; Hadland et al., 2017; Mosher et al., 2017; Gaither et al., 2016; Xie et
al., 2014). Specifically, studies using the Nationwide Emergency Department Sample (NEDS)
have used the following: (1) individual variables – age, gender, primary payer, annual median
income, patient location; and (2) hospital variables – control/ownership, region, designation; and
type of emergency department event (disposition) including treated & released, admitted to same
hospital, transferred to another or died (Chandwani et al., 2013; Mejia et al., 2018; Upadhyay et
al., 2018; Rivera et al., 2017; Singh et al., 2016; Wall et al., 2015; Wang et al., 2015). In 2013,
only 0.4% of 15-17 year olds compared to 12.0% of 18 year olds and older with prescription
OUD; and only 2.4% of 15-17 year olds compared to 26.3% of 18 year olds and older with
heroin use disorder received medication-assisted treatment (MAT) (Feder et al., 2017).
Importance of emergency departments in opioid use disorder
Emergency departments (EDs) are engaged in managing the untoward consequences of
inappropriately prescribed opioids (Xie et al, 2014; Duber et al., 2018; Salzman et al., 2020).
About 305,900 ED visits were related to the nonmedical use of opioids in 2008, a 111% increase
from the 144,600 ED visits in 2004 (Xie et al, 2014).
State-level opioid policies
State lawmakers in the United States are engaging different sectors such as health,
criminal justice, human services, and so on to create innovative policies aimed addressing the
current opioid crisis deemed as a public health emergency (U.S HHS, 2017). These efforts are
going on in addition to ensuring appropriate and needed access to pain management. A minimum
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of 33 states had enacted legislation related to opioid prescription limits as of October l, 2018
(Blackman, 2017).
As of July 1 2017, in United States, 49 States, District of Columbia, and St. Louis County
in Missouri have operational Prescription Drug Monitoring Programs (PDMPs) that have
capacity to receive and distribute controlled substance prescription information to authorized
users (National Alliance for Model State Drug Laws, 2017).
As of 2019, in United States, 49 States and the District of Columbia with exception of
Wyoming have operational Opioid Treatment Programs (OTP) that provide medication-assisted
treatment (MAT) – use of medications with counseling and behavioral therapies to provide
holistic treatment – for individuals diagnosed with opioid use disorder (OUD) and to prevent
opioid overdose (Kaiser Family Foundation, 2019; SAMHSA, 2015, 2019).
In spite of state-level opioid policies, there are still geographic variations to the opioid
crisis. In addition to causes of the geographic variations in opioid crisis and per capita cost of
care stated above, other factors may be responsible for observed state-level variations in opioid
usage in United States. These include (Martin et al., 2016): (1) Availability of, access to, scope
of regulation, and use of Prescription Drug Monitoring Programs (PDMPs). (2) Attitudes of the
population regarding pain and opioid-containing substances. (3) Attitudes of law enforcement
towards individuals using opioids and incarceration of such individuals. (4) Judicial enforcement
using drug courts or mandating treatment versus imprisonment. (5) Addiction treatment
availability and referrals to these facilities and other treatment resources. (6) Addiction treatment
reimbursement. (7) Reimbursement of insurance for screening and analysis of risk. (8) Heroin
and other illicitly produced synthetic opioids availability in the community. (9) Healthcare
providers and patients education. (10) Oversight of patients taking and providers prescribing
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controlled substances. (11) Community resources and involvement in response to opioid crisis.
(12) Probable effects of genetic variations or cultural influences on specific populations.
Therefore, to address convincingly the opioid crisis, an understanding of the specific
features of the opioid crisis in individual states and geographic regions is necessary in addition to
policies.
Policy/intervention evaluation
Effect of policies on prescribing practices – Following a uniform rise in overall national
rate of opioid prescribing beginning in 2006, the total quantity of opioid prescriptions written
and dispensed reached a climax in 2012 at approximately 255.2 million prescriptions equivalent
to a prescribing rate of 81.3 prescriptions per 100 persons (Centers for Disease Control and
Prevention, 2018b). Thereafter, from 2012 to 2017, overall national prescribing rates of opioids
analgesics decreased. This decline in overall national opioid analgesic prescribing rate reached
its ebb in 2017, the lowest in over 10 years for an estimated total of 191.2 million prescriptions
equivalent to a prescribing rate per 100 persons of 58.7 prescriptions (Bao et al., 2016, 2018;
Centers for Disease Control and Prevention, 2018b; Bohnert et al., 2018;). Policies related to use
of state prescription drug monitoring programs (PDMPs) particularly comprehensive legislative
mandates to use PDMPs and laws allowing healthcare providers who prescribe opioids to
delegate use of PDMPs to their office staff have been more effective compared to laws
compelling state participation in interstate sharing of PDMP data at reducing opioid prescribing
rates (Bao et al., 2018).
In 2017, however, certain areas across the United States still witnessed very high opioid
prescribing rates perhaps due in part to consistently higher quantity of opioids in morphine
milligram equivalents (MME) prescribed per person, causes of geographic variations, and other
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factors discussed earlier. For instance, some United States counties had prescribing rates per 100
persons that were seven times higher than the national average of 58.7. In addition, opioid
analgesics prescriptions still being dispensed in 16% of counties in United States were enough
for everyone in the nation to have one (Centers for Disease Control and Prevention, 2018b).
Thus, it is reasonable to conclude that though policies limiting supply of prescription and other
sources of legal opioids are necessary, they are not sufficient to address the opioid crisis.
Effect of policies on opioid overdoses – The prescribing rate of opioid analgesics had
declined annually since 2012 reaching a 10-year low in 2017 (Centers for Disease Control and
Prevention, 2018b). However, national and state-level opioid overdose deaths continued to rise
within the same period from 2012 to 2017 (Kaiser Family Foundation, 2017a; National Institute
on Drug Abuse, 2018a). Plausible reasons for this may be as discussed earlier, persistently higher
MMEs of opioids still prescribed per person, clusters of counties around the country still
prescribing opioids over five times that of the national average, and high dispensing rate of
opioid analgesics by almost 20% of counties nationwide (Centers for Disease Control and
Prevention, 2018b). In addition to over-prescription in some parts of the country, it is not
possible to rule out diversion and misuse of prescription opioids. Furthermore, prescription
opioids even when prescribing rates have declined are still precursors to addiction and
transitioning to illegal opioids and a reason for rising opioid overdose mortalities (Compton &
Wargo, 2018). The above reasons were supported in a systematic review by Fink and colleagues
in 2018, which revealed that the impact of implementing PDMPs on opioid overdoses was
equivocal because there were evidences that implementing PDMPs was associated with
declining or rising nonfatal or fatal opioid overdoses (Fink et al, 2018).
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Effect of policy on opioid use disorder – Medication-assisted treatment (MAT) is
effective for treating opioid use disorder (OUD). Use of MAT leads to: (1) increased social
functioning and retention in treatment program of affected individuals; (2) reduced, use of
opioids, overdosing on opioids, criminal activities, risky behaviors promoting transmission of
HIV and hepatitis C virus (HCV), morbidity and mortality (Mattick et al., 2009, 2014; Schwartz
et al., 2013; SAMHSA, 2015; Connery, 2015; US HHS, 2016).
Medications used in MAT include, buprenorphine (Suboxone®, Subutex®), methadone, and
extended release naltrexone (Vivitrol®), with buprenorphine and methadone considered essential
medicines (WHO, 2004; National Institute on Drug Abuse, 2018a, 2016). However, these
medications are not extensively used and where they are used; access to the medications is a
major issue (Jones et al., 2018). The nationwide percentage of admissions for opioid treatment
with treatment plans including receipt of medications such as MAT decreased from 35.2% in
2002 to 27.6% in 2013 before increasing to 36.9% in 2015 then decreasing again to 33.5% in
2016. This trend was occurring while total opioid admissions increased between 2002 and 2016.
(SAMHSA, 2014, 2017, 2018). This fluctuating trend may have been due to initially insufficient
treatment capacity (responsible for the 2002-2013 decline) (Jones et al, 2015; Jones et al., 2018)
which progressively improved and/or availability of multiple treatment options in U.S. States
(responsible for the 2013-2015 rise and 2015-2016 decline) (Jones et al., 2018).
Overall, the impact of MAT on OUD has been equivocal (Kampman & Jarvis, 2015;
Potter et al., 2015; Weiss et al., 2015). Medication assisted treatment (MAT) has proven
effectiveness in treating OUD following initiation of MAT in an estimated 50% of patients with
prescription OUD at 18 months (Potter et al., 2015) and 61% of patients with prescription OUD
at 42 months (Weiss et al., 2015). Conversely, it has proven to be ineffective in approximately
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50% and 39% of patients with prescription OUD at 18 and 42 months follow-up post-initiation
of MAT respectively (Potter et al., 2015; Weiss et al., 2015).
Selected state-level comparison of the opioid crisis
The states of Texas, New York, and Kentucky are selected to highlight the variation in
statistics of the opioid crisis in the United States.
Texas – Is located in southern United States. Specifically, in the West South Central division
where the overall burden of the opioid epidemic is light. There are very few available facilities
located in Texas, which, provide some but not all three forms of MAT. The state of Texas has
not expanded Medicaid (SAMHSA, 2017; National Institute on Drug Abuse, 2018b; Jones et al.,
2018).
New York – Is located in the northeast United States. Specifically, in the Middle Atlantic
division where the overall burden of the opioid epidemic is relatively heavy. There are many
facilities located in New York providing all three forms of MAT. These facilities are clustered
together. The state of New York has expanded Medicaid (SAMHSA, 2017; National Institute on
Drug Abuse, 2018b; Jones et al., 2018).
Kentucky – Is located in the southern United State. Specifically, in the East South Central
division where the overall burden of the opioid epidemic is heavy. There are very few available
facilities located in Kentucky, which provide some but not all three forms of MAT. The state of
Kentucky has expanded Medicaid. (SAMHSA, 2017; National Institute on Drug Abuse, 2018b;
Jones et al., 2018).
In 2016, Texas had an opioid-related overdose death rate of 4.9 deaths per 100,000 persons.
However, the number of heroin and synthetic opioids death rates has steadily increased since
2010. New York State had an opioid-related overdose death rate of 15.1 deaths per 100,000
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persons in the same year. The heroin-related and synthetic opioids deaths were over two times
and ten times more since 2012. Similarly, in Kentucky with an opioid-related overdose death rate
of 23.6 deaths per 100,000 persons, the heroin-related deaths more than doubled and synthetic
opioids deaths were over six times more since 2012.
A comparative analysis of the opioid crisis by the numbers between Texas, New York, and
Kentucky is shown below.
Table 2. Comparative Analysis of Opioid Crisis between the States of Texas, New York, and
Kentucky

Texas

States
New York

Kentucky

Opioid pain reliever
prescriptions (opioid
prescriptions per 100
persons) (2016)

57.6

42.7

97.2

70.6

Total number of
prescriptions (millions)
(2016)

15.44

9.53

4.18

214.88

Opioid related overdose
deaths (2016)

1,375

1,641

989

42,000

Opioid related overdose
death rates (deaths per
100,000 persons) (2016)

4.9

15.1

23.6

13.3

Total per capita cost of
opioid crisis ($ per
resident) (2015)

653

1,850

2,412

---

Non-mortality per capita
cost of opioid crisis ($ per
resident) (2015)

144

320

205

---

Total healthcare
expenditure per capita by
state of residence ($)
(2015)

7,006.31

9,789.61

8,013.50

8,054.55

Characteristics

National Average

Sources: (Kaiser Family Foundation, 2017b; National Institute on Drug Abuse, 2018b; Centers
for Disease Control and Prevention, 2018b).
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Public Health Significance
The opioid crisis in America appears to be worsening. State-level policies legitimizing
interventions such as use of Prescription Drug Monitoring Programs (PDMPs) that have capacity
to receive and distribute controlled substance prescription information and Opioid Treatment
Programs (OTP) that provide medication-assisted treatment (MAT) for opioid use disorder
(OUD) and to prevent opioid overdose have made modest impacts on prescribing practices,
opioid overdoses, and opioid use disorder. These interventions though promising have
challenges, which need to be adequately addressed if they are to make significant positive
impacts on the opioid crisis.
This research will provide most current prevalence of diagnosing and treating OUD in
12-18 year olds and those over 18 with OUD based on their ED disposition. In addition, this
research will use a robust sample of nationally representative data including those 12 years of
age and older. Furthermore, it will provide accurate estimates to guide policy and program
implementation regarding management of opioid use disorder in the emergency department.
Specific Aims
The specific aims of this research are:
Aim 1:
To systematically identify, appraise, and collect state-by-state level data on status of medicationassisted treatment (MAT) policies, MAT medication coverage status for OUD treatment,
Medicaid expansion status, and Medicaid section 1115 behavioral health waiver status for OUD
treatment in all 50 states and the District of Columbia captured in the literature.
Aim 2:
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To examine individual characteristics (Primary payer, Annual median income, Patient location,
and Type of emergency department event), hospital characteristics (Control/Ownership, Region,
and Designation), and state-level policy characteristics (MAT policy status, MAT medication
coverage status for treating OUD, Medicaid expansion status, and Medicaid section 1115
behavioral health waiver status for OUD treatment) associated with prevalence of emergency
department diagnosis and treatment of any opioid use disorder (OUD) in U.S. population 12
years and older from January 2016 to December 2016 captured in the Nationwide Emergency
Department Sample (NEDS) database.
Conceptual Research Model
Research Models Referenced in the Literature
General Model of State Policy Adoption (Miller, 2005) – The general model of state
policy adoption posits that the determinants of adoption of policy arise from both a state’s
external and internal environment. External factors include policy adoptions by other states and
federal assistance, law and regulation. Internal factors comprise the economic and political
circumstances of a particular state in addition to baseline program and policy characteristics.
Socioeconomic factors directly influence Medicaid program and other policy attributes; and
indirectly influence Medicaid program and other policy attributes by first influencing political
system development, which, in turn, produces policy outputs that feedback into the
socioeconomic and/or political environment.
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Source: https://www.sciencedirect.com/science/article/pii/S0277953605002376
Structure, Process and Outcomes Framework by Avedis Donabedian – Avedis
Donabedian described a widely adopted and adapted framework for assessing, investigating, and
understanding quality of care using the structure, process and outcomes constructs (Donabedian,
1966; Donabedian, 2005).
Donabedian’s reasoning was that the definition of outcomes and types of measures
selected for measurement of outcomes were both imperative for understanding quality in health
care. In addition, in his landmark article Donabedian described the significant role processrelated factors played in understanding and evaluating quality. He noted that rooted in the
processes of care are values, standards and normative judgments that drive performance of
patient care activities to improve patient health. Furthermore, Donabedian also highlighted the
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important influence of structure of care or physical and organizational context such as personnel,
equipment, facilities, financial and operational processes and so on that support healthcare on
quality (Donabedian, 1966; McDonald et al., 2007).
Donabedian’s structure-process-outcomes framework is flexible and allows for different
interpretations and applications in different circumstances (Donabedian, 1966; Donabedian,
2005).

Source: https://www.ncbi.nlm.nih.gov/books/NBK44008/figure/A25995/?report=objectonly
Research Model
The model for this study combined Donabedian’s structure-process-outcomes framework
and the General Model of State Policy Adoption. In this study, Donabedian’s framework was
embedded within the General Model of State Policy Adoption. The relationships between both
models and the study aims are depicted thus:
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STRUCTURE
Patient Characteristics:
Insurance status, Annual
median income, Patient
location
Hospital Characteristics:
Control/Ownership, Region,
Designation

PROCESS

ED Event:
Treated & released,
Admitted to same
hospital,
Transferred, Died

OUTCOMES

Aim 2

Prevalence

State Policy Characteristics:
MAT policy status, MAT
medication coverage status,
Medicaid expansion status,
Medicaid section 1115
behavioral health waiver status
State-Level Opioid Policies: Aim 1
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METHODS
Study Design
This research involved a retrospective secondary data analysis of the Nationwide
Emergency Department Sample (NEDS) from January 1, 2016 to December 31, 2016.
Data Sources
Nationwide Emergency Department Sample (NEDS) – The NEDS is the largest all-payer
emergency department (ED) database in the United States, yielding national estimates of
hospital-based ED visits. NEDS was developed for the Healthcare Cost and Utilization Project
(HCUP) and is maintained by the Agency for Healthcare Research and Quality (AHRQ). NEDS
produces regional and national estimates about hospital-owned emergency department (ED)
visits across the United States. The NEDS describes ED visits, regardless of whether they result
in admission. Information includes geographic characteristics, hospital characteristics, patient
characteristics, and the nature of visits (e.g., common diagnoses for ED visits). The NEDS was
constructed using the Healthcare Cost and Utilization Project (HCUP) State Emergency
Department Databases (SEDD) and the State Inpatient Databases (SID). HCUP data inform
decision-making at the national, state, and community levels. The SEDD capture discharge
information on ED visits that do not result in an admission (i.e., treat-and-release visits, transfers
to another hospital, and deaths). The SID contain information on patients initially seen in the ED
and then admitted to the same hospital.
The 2016 NEDS includes a full calendar year of data with diagnosis and procedure codes
reported using the International Classification of Diseases, Tenth Revision, Clinical
Modification/Procedure Coding System ICD-10-CM/PCS).
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American Society of Addiction Medicine (ASAM) state reports (American Society of
Addiction Medicine et al., 2013); Substance Abuse and Mental Health Services Administration
(SAMHSA) Office of Policy, Planning and Innovation State Medicaid coverage reports
(Substance Abuse and Mental Health Services Administration et al., 2014, 2018); and Kaiser
Family Foundation (KFF) report on the opioid epidemic (Kaiser Family Foundation, 2018b,
2019a, 2019b) – for nationwide state level medication-assisted treatment (MAT) policy, MAT
medication coverage status, Medicaid expansion status, and Medicaid section 1115 behavioral
health waiver status data. These data provided the state-by-state summary of medication-assisted
treatment (MAT) policy status, Medicaid coverage status of the MAT medications for treating
OUD, Medicaid expansion status, and Medicaid section 1115 behavioral health waiver status
used in this study.
Study Population
Target Universe
Emergency departments (ED) in community, nonrehabilitation U.S. hospital-owned ED
that reported total ED visits in the American Hospital Association (AHA) Annual Survey
Database. Equivalent to 144,842,742 ED events in 2016.
Exclusion criterion – non-rural hospitals that reported less than ten ED visits in a year.
Sampling Frame
Hospital-owned ED in the 35 States and the District of Columbia that provided
information on ED visits that result and do not result in admission. The sampling frame of the
NEDS was limited to a subset of the universe: hospital-owned ED in the States and District of
Columbia for which Healthcare Cost and Utilization Project (HCUP) ED data (SID and SEDD)
were available. The list of hospital-owned ED in the sampling frame consisted of all AHA
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community, nonrehabilitation hospitals that reported total ED visits in each of the sampling
frame States and District of Columbia that could be matched to the ED data provided to HCUP.
If an ED in the AHA survey could not be matched to the ED data provided by the HCUP data
source, it was eliminated from the sampling frame (but not from the target universe). The HCUP
hospitals were required to be represented in the AHA data and have no more than 90 percent of
their ED visits resulting in admission. Equivalent to 113,306,272 ED events in 2016.
Exclusion criterion – HCUP hospitals that were not represented in the AHA data and had more
than 90 percent of their ED visits resulting in admission.
Sample Size Calculation and/or Study Power
Sample size
The 2016 NEDS is a 20% stratified probability sample of target universe drawn from the
sampling frame based on five hospital-based stratification variables including, United States
Census region, trauma center designation, urban-rural hospital location, ownership, and teaching
status. It therefore represented the diversity of hospitals across the United States. A sample size
of 20 percent was based on previous experience with similar research databases. A larger sample
would be cumbersome for data users, given that a 20 percent sample contains about 30 million
records. A 20 percent sample also enables the user to split the NEDS into two 10 percent
subsamples for estimation and validation of models. Therefore, the 2016 NEDS contained
32,680,232 ED visits in 953 hospitals across 35 states and the District of Columbia. Poststratification discharge weights defined by the Healthcare Cost and Utilization Project (HCUP)
were used to calculate national estimates. The use of these weights enabled each HCUP database
discharge entry to be adjusted to estimate values from specific portions of the overall United
States population. The number of ED visits weighted for national estimates was 144,842,742. In
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2016, the national rate of opioid-related ED visits per 100,000 population was 243.5 with a range
of 223 to 268.
The HCUP states in the 2016 NEDS included; Arizona, Arkansas, California, Connecticut,
District of Columbia, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kansas, Kentucky,
Maine, Maryland, Massachusetts, Minnesota, Mississippi, Missouri, Montana, Nebraska,
Nevada, New Jersey, New York, North Carolina, North Dakota, Ohio, Oregon, Rhode Island,
South Carolina, South Dakota, Tennessee, Utah, Vermont, Wisconsin, and Wyoming.
Figure of HCUP States and the District of Columbia included in the 2016 NEDS.

Source: https://www.hcup-us.ahrq.gov/db/nation/neds/NEDS_Introduction_2016.jsp#ta1
Note: The above graphic outlines states in the NEDS by Region. In the Western region, AZ, CA,
HI, MT, NV, OR, UT, WY were in the HCUP NEDS. The following states were not in the
NEDS in this region - AK, CO, ID, NM, WA. In the Midwestern region, IA, IN, IL, KS, MN,
MO, ND, NE, OH, SD, WI were in the HCUP NEDS. The following state was not in the NEDS
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in this region - MI. In the Northeastern region, CT, MA, ME, NJ, NY, RI, VT were in the HCUP
NEDS. The following states were not in the NEDS in this region - NH, PA. In the Southern
region, AR, DC, FL, GA, KY, MD, MS, NC, SC, TN, TX were in the HCUP NEDS. The
following states were not in the NEDS in this region - AL, DE, LA, OK, VA, WV.
Cases of opioid use disorder (OUD) were identified using International Classification of
Disease, Tenth Revision, Clinical Modification (ICD-10-CM) codes. These cases were assessed
for characteristics associated with prevalence including, (1) Patient (Primary payer, Annual
median income, Patient location, and Type of emergency department event – treated & released,
admitted to same hospital, transferred to another or died). (2) Hospital (Control/Ownership,
Region, and Designation).
The American Psychiatric Association Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition (DSM-5) Classification recommended ICD-10-CM codes for opioid use
disorder (OUD) beginning October 1, 2017 are F11.1*for opioid abuse and F11.2* for opioid
dependence. The code for uncomplicated opioid abuse is F11.10, which is applicable to mild
OUD. The code for uncomplicated opioid dependence is F11.20 which is applicable to moderate
and severe OUD (ICD-10-CM Diagnosis Code, 2018; American Psychiatric Association, 2013).
Study Power
For the systematic review, following good research practice, a convenience sample size
of the 35 states and the District of Columbia which contributed to the 2016 NEDS database was
used in this study.
For the secondary analysis of the 2016 NEDS cross-sectional dataset of this study, the
minimal required sample size was calculated based on a power of 80% and a significance level
(α) of 0.05.
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To calculate the sample size required for this survey study, the follow were needed
(Abramson, 2008; Selwyn, 2011):
“p” – A reasonably close estimate of estimate of the actual prevalence – if in
doubt, 50% was used; this maximized the sample size and, hence, erred on the safe side.
“d” – The maximum acceptable difference between the estimated prevalence
(based on the sample) and the actual prevalence; this “acceptable margin of error” was
half the confidence interval.
“t” – The required confidence interval – usually 95%
Also, the size of the population; its effect on the calculated sample size – the
Finite Population Correction (f.p.c) was small, unless the population was very
small.
Initial sample size (n) calculation;
Using the formula, n = (t2pq)/d2
Where n=sample size; t=Z of 95% confidence=1.96; p=prevalence estimate=50%;
q=1-p=50%; d=absolute error or sampling error=10%.
n = (1.962*0.5*0.5)/0.12 = 96.04 = 97
Sample size calculation corrected for Finite Population Correction (f.p.c);
Based on good sampling practice, sample was ≥10% of the sample size of 32,680,232 ED
visits. In this research, 2016 NEDS was 20% of probability sample of target universe
drawn from the sampling frame.
Using the sample size of emergency departments (ED) in community, nonrehabilitation U.S.
hospital-owned EDs that reported total ED visits in the American Hospital Association (AHA)
Annual Survey Database, N = 32,680,232
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Initial sample size, n = 97
Thus, sampling fraction = n/N = 97/144,842,742 = 6.7*10-7 x100% = 6.7*10-5%
Therefore, since the sampling fraction was very low, the f.p.c was close to unity and the
correction had a negligible influence and was omitted (Armitage et al., 2002).
Sample size calculation corrected for nonresponse (NR);
Based on good sampling practice, an NR of 10% was expected.
Therefore, the new sample size, n1 = n/(1-NR) = 97/(1-0.1) = 107.8 = 108.
Based on a sample size of 108, calculated power using STATA version 15.0 = 55%. But based
on good sampling practice, a power of at least 80% was expected which amounted to a
calculated sample size of 194. However, 2016 NEDS sample size was 32,680,232 which
provided adequate size to detect any significant difference.
Data Collection and Management
Discharge-level administrative NEDS data was collected based on efforts of hospitals in
participating states that maintain statewide data systems. Unweighted ED visit data were
collected on actual visits, then weighted proportionately to total number of ED visits in the
country based on the sampling strategy. The NEDS is a stratified single-stage cluster sample of
state-level ED data reported to healthcare cost and utilization project (HCUP).
All emergency department (ED) discharge-level data totaling 32,680,232 ED visits in 953
hospitals across 35 states and the District of Columbia contributing to and collected in the 2016
NEDS were used in this study. This dataset provided the largest repository of individual level
discharge data from all ED visits nationwide capable of providing patient and hospital
characteristics associated with prevalence of diagnosing and treating OUD in U.S. Emergency
Departments.
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Data security and confidentiality – Data in the 2016 NEDS database were recoded to
ensure ease of analysis. Missing data were excluded from the final dataset for analysis.
Data location and management – Final dataset for analysis was password protected and
study materials secured in a locked cabinet.
Quality Control
The following quality control procedures were used to assess data quality and perform
basic editing for the NEDS:
Quality control editing procedures – Data editing was performed using the following
explicit rules. (a) Made the data usable without extensive further editing. (b) Confirmed that data
values were valid, internally consistent, and consistent with established norms, when feasible. (c)
Used some edit procedures to set questionable and inconsistent values to inconsistent (.C or
negative 6-filled). Used other edit procedures only to tabulate edit failures. Used the latter to
evaluate whether systematic problems exist. (d) Never "fix" or imputed data. Set invalid or
inconsistent values to special missing values. This preserved the analyst's ability to investigate
data anomalies. (e) Some data elements were coded more reliably because they related to
reimbursement. For example, diagnoses, procedures, age, sex, and discharge disposition were
part of the algorithm to assign Diagnosis Related Group (DRG) on an inpatient record. (f)
Tabulated instances of edit failures and used these to assess data quality for each data source.
Quality review procedure – An independent contractor reviewed the following statistics
for the 2016 NEDS. (a) Means, number of missing and non-missing values, minimum, and
maximum for all numeric data elements. (b) Mean, median, and extreme values for continuous
variables such as length of stay and charges. (c) Frequency distributions for all categorical and
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some continuous data elements. (d) Cross frequencies for closely related data elements (e.g.,
point of origin compared to admission type).
Automated quality review control procedures – Each discharge record was subjected to
the following procedures. (a) To assess validity of values – For numeric data: Verifying numeric
data as numeric. Checking the range against legal values documented by the data source.
Checking the range against standard norms (e.g., length of stay is a non-negative value; age in
years is between 0 and 124, the maximum allowed by the DRG grouper). Checking the values
against the maximum allowed for the data element (e.g., birth weight less than 20 pounds). For
character data: Verifying against norms, when feasible (e.g., diagnosis codes and procedure
codes). (b) To assess internal consistency – Comparing values of related data elements (e.g., a
procedure of hysterectomy should appear with a sex of female; admission date should occur
before discharge date). If an inconsistency involved a critical data element (such as discharge
date and admission date), as much information as reasonable was retained. For example, If
discharge date fell before admission date, discharge date was retained and admission date and
length of stay set to inconsistent (.C or negative 6-filled). If discharge date was invalid (e.g.,
February 30), discharge quarter and discharge year were retained. (c) To assess consistency with
established norms – Comparing values to an established norm (e.g., maternal diagnoses should
occur with an age between 10 and 55 years).
Measures
Individual patient encounters resulting in a diagnosis of any opioid-related incidents
including the diagnosis of OUD were identified in NEDS using ICD-10-CM diagnostic codes.
According to the DSM-5 classification of the American Psychiatric Association, beginning
October 1, 2017, ICD-10-CM codes for OUD are F11.1* for opioid abuse and F11.2* for opioid
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dependence (WHO, 1992, 1993). This study used F11.10, the code for uncomplicated opioid
abuse which was applicable to mild OUD and F11.20, the code for uncomplicated opioid
dependence which was applicable to moderate and severe OUD (ICD-10-CM Diagnosis Code,
2018; American Psychiatric Association, 2013). A composite variable “OUD_Condition” based
on whether the individual patient encounter resulted in a diagnosis and treatment of OUD,
specifically uncomplicated opioid abuse or uncomplicated opioid dependence was created.
Depending on the presence of opioid abuse or opioid dependence, “OUD_Condition was then
recoded as ‘0’ – Uncomplicated opioid abuse; and ‘1’ – Uncomplicated opioid dependence.
These cases of OUD were assessed for factors associated with prevalence (patient demographic –
Primary payer, Annual median income, Patient location, and Type of emergency department
event – treated & released, admitted to same hospital, transferred to another or died; hospital –
Control/Ownership, Region, and Designation; and state-level policy – MAT policy status, MAT
medication coverage status, Medicaid expansion status, and Medicaid section 1115 behavioral
health waiver status).
The cohort of cases in this study were patients 12 years and older. Children from 12 years
were included in this study because there has been significant increases in opioid prescribing
across all age groups observed in recent years (Binswanger & Glanz, 2015). In addition, opioids
have become the most commonly initiated drugs of abuse among youth. There has been a sixfold increase of unintentional opioid poisonings in youth in the last 10 years. Furthermore, 5.4%
of 12-17 year olds and 10% of 18-25 year olds reported nonmedical use of prescription opioids
in 2012 (Binswanger & Glanz, 2015). Therefore, treatment plans that are effective, practical, and
scalable are needed for the young population with OUD (Borodovsky et al, 2018).
Variables
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Outcome variables: The outcome variables for this study included: (i) State-level opioid
policy – which was defined as the type of state-by-state opioid policy in existence. Specifically,
state-level opioid policy were characterized by, (a) MAT policy status – presence or not of statelevel MAT policy. (b) MAT medication coverage status – coverage of all three MAT
medications used for OUD treatment (comprehensive coverage) or coverage of two or less of
MAT medication used for OUD treatment (non-comprehensive coverage) (Grogan et al, 2016;
Blanchard et al, 2018). (c) Medicaid expansion status – number of states that have adopted and
not adopted Medicaid expansion. (d) Medicaid section 1115 behavioral health waiver status –
number of states that have approved and not approved for behavioral health exclusion waivers
for OUD treatment. (ii) Prevalence – which was defined as the proportion of cases of opioid use
disorder (OUD) diagnosed and treated in the Emergency Department (ED) within a 12-month
period from January 2016 to December 2016.
Predictor variables: The predictor variables in this study were grouped into two
categories. (1) Primary predictor variable – (i) Opioid use disorder (OUD) condition – which was
defined as the presence of a diagnosis of uncomplicated opioid abuse and uncomplicated opioid
dependence during an individual patient encounter at the ED within a 12-month period from
January 2016 to December 2016. (2) Covariates – (i) Patient characteristics – primary payer,
annual median income, patient location and ED event. (ii) Hospital characteristics –
control/ownership, region, and designation. (iii) State-level policy characteristics – MAT policy
status, MAT medication coverage status, Medicaid expansion status, and Medicaid section 1115
behavioral health waiver status.
Measurement Matrix
Outcome Variables
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Variable
category

State-Level
Opioid Policy

Prevalence

Variable

Opioid Policy

Prevalence

Definition

Source

Characteristics of statelevel opioid policy
(including: MAT policy
status – not present=0,
present=1; MAT
medication status – noncomprehensive=0,
comprehensive=1;
Medicaid expansion status
– not adopted=0,
adopted=1, and Medicaid
section 1115 behavioral
health waiver status – not
approved=0, approved=1)

American
Society of
Addiction
Medicine
(ASAM) State
Report,
Substance
Abuse and
Mental Health
Services
Administration
(SAMHSA),
and Kaiser
Family
Foundation
(KFF) Report

The proportion of cases of
opioid use disorder (OUD)
diagnosed and treated for
in the Emergency
Department (ED) within a
12-month period from
January 2016 to December
2016

Nationwide
Emergency
Department
Sample
(NEDS)

Related
Aim

Type

Aim 1

Systematic review
of state-by-state
opioid policies

Aim 2

Continuous

Related
Aim

Type

Predictor variables
Variable
category

Variable

Definition

Source
Primary

OUD Diagnosis

OUD_Condition

Presence of a diagnosis of
opioid abuse or
dependence during an
individual patient
encounter at the ED within
a 12-month period from
January 2016 to December
2016. (including, 0=
diagnosed opioid abuse ,
1= diagnosed opioid
dependence)

Composite
derived from
Nationwide
Emergency
Department
Sample
(NEDS)

Aim 2

Categorical
(Binary)

Covariates
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Primary payer

Expected primary payer of
ED services (including,
1=Medicare, 2=Medicaid,
3=Private including HMO,
4=Self-pay, 5=No charge,
6=Other)

Annual Median
Income

National quartile of
median household income
estimated using patient's
residential zip code
(include, 1=$1-$42,999,
2=$43,000-$53,999,
3=$54,000-$70,999, and
4=≥$71,000)

Patient location

Urban-rural designation
of patient’s county of
residence (include, 1=large
central metropolitan,
2=large fringe
metropolitan, 3=medium
metropolitan, and 4=small
metropolitan,
5=micropolitan, 6=not
metropolitan or
micropolitan)

ED Event

Type of patient ED event
(include, 1=treated &
released, 2=admitted to
same hospital,
3=transferred to another
hospital, 9=died)

Patient
Characteristics

Hospital
Characteristics

Ownership status of
ED/hospital (include,
0=all,
1=public[government,
non-Federal,
Control/Owners
2=voluntary[private, nothip
for-profit],
3=proprietary[private,
investor-owned/for-profit],
4=private[private
voluntary/proprietary])
Region

Region of the U.S.
hospital is located
(include, 1=Northeast,

NEDS

Aim 2

Categorical
(Nominal)

NEDS

Aim 2

Categorical
(Ordinal)

NEDS

Aim 2

Categorical
(Nominal)

NEDS

Aim 2

Categorical
(Nominal)

Nationwide
Emergency
Department
Sample
(NEDS)

Aim 2

Categorical
(Nominal)

NEDS

Aim 2

Categorical
(Nominal)
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2=Midwest, 3=South, and
4=West)

Designation

MAT Policy
Status

State-Policy
Characteristics

Hospital urban-rural
designation (include,
1=large metropolitan area,
2=small metropolitan area,
3=Micropolitan area, and
4=Non-urban residual)
Presence or absence of
MAT policy. (including,
0=Not present, 1=Present)

NEDS

Aim 2

Categorical
(Nominal)

ASAM State
Report,
SAMHSA,
and KFF
Report

Aims 1& 2

Categorical
(Binary)

MAT
Medication
Coverage
Status

Presence or absence of
MAT medication
coverage status.
(including, 0= noncomprehensive
coverage, 1=has
comprehensive
coverage)

ASAM State
Report,
SAMHSA,
and KFF
Report

Aims 1& 2

Categorical
(Binary)

Medicaid
Expansion
Status

Adoption or not
Medicaid expansion.
(including, 0= not
adopted, 1=Adopted)

KFF Report

Aims 1& 2

Categorical
(Binary)

Medicaid
Section 1115
Behavioral
Health Waiver
Status

Section 1115 behavioral
health waiver status.
(including, 0=not
approved, 1=Approved)

KFF Report

Aims 1& 2

Categorical
(Binary)

Data Analysis
Overview
The final dataset for analysis was organized, recoded and analyzed manually by research
staff.
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Descriptive statistics including frequency and proportions were used to analyze the final data
collected. In addition to hierarchical linear regression model (HLM) was used to analyze the
final data collected.
Data analysis was performed using Statistical Package for Social Sciences (SPSS) version 25.0
developed by IBM Corporation.
Secondary analyses
Aim 1: To systematically identify, appraise, and collect state-by-state level data on status of
medication-assisted treatment (MAT) policies, MAT medication coverage status for OUD
treatment, Medicaid expansion status, and Medicaid section 1115 behavioral health waiver status
for OUD treatment in all 50 states and the District of Columbia captured in the literature.
Methods – Review of the identified data sources – American Society of Addiction
Medicine (ASAM) state reports; Substance Abuse and Mental Health Services Administration
(SAMHSA) Office of Policy, Planning and Innovation State Medicaid coverage reports; and
Kaiser Family Foundation reports on the opioid epidemic was performed to identify, appraise
and collect relevant data on nationwide state-level opioid policy status, MAT medication
coverage status for treating OUD, Medicaid expansion status, and Medicaid section 1115
behavioral health waiver status for OUD treatment. While, the aim of the review which was to
identify, appraise, and collect state-level opioid policies in all 50 states and the District of
Columbia in the United States captured in the literature was accomplished, only policies
specifically within the 35 states of the US and the District of Columbia contribution to the 2016
NEDS were used in the analysis. These included; Arizona, Arkansas, California, Connecticut,
District of Columbia, Florida, Georgia, Hawaii, Iowa, Illinois, Indiana, Kansas, Kentucky,
Maine, Maryland, Massachusetts, Minnesota, Missouri, Mississippi, Montana, North Carolina,
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North Dakota, Nebraska, New Jersey, Nevada, New York, Ohio, Oregon, Rhode Island, South
Carolina, South Dakota, Tennessee, Utah, Vermont, Wisconsin, and Wyoming. The University
of Texas Health Science Center at Houston Committee for the Protection of Human Subjects –
also known as Institutional Review Board (IRB) – approval was not required for this process as
no human subjects were needed.
Results – Findings from each of the 50 States opioid policy evaluated for specific criteria
including MAT policy status, MAT medication coverage status for treating OUD, Medicaid
expansion status and Medicaid section 1115 behavioral health waiver status was presented Table
2 shown below.
Aim 2: To examine individual or patient characteristics (Primary payer, Annual median income,
Patient location and Type of emergency department event), hospital characteristics
(Control/Ownership, Region, and Designation), and state-level policy characteristics (Opioid
policy status, MAT medication coverage status for treating OUD, Medicaid expansion status,
and Medicaid section 1115 behavioral health waiver status for OUD treatment) associated with
prevalence of emergency department diagnosis and treatment of any opioid use disorder (OUD)
in U.S. population 12 years and older from January 2016 to December 2016 captured in the
Nationwide Emergency Department Sample (NEDS) database.
Method – Data preparation: Core dataset – For this study, this dataset was also known as
the patient-level dataset. Only the variables of interest were retained in the core (patient-level)
dataset. These included, “DX_OUD” – the ICD-10-CM Diagnosis for OUD; “PAY1” – the
primary expected payer (uniform), “ZIPINC_QRTL” – the median household income national
quartile for patient zip code, “PL_NCHS” – the patient location: NCHS urban-rural code, and
“EDEVENT” – the type of ED event. A new variable “nDX_OUD” was created to represent the

56

string to numeric recode of OUD diagnosis variable “DX_OUD”. Using ICD-10-CM codes, the
diagnoses of any opioid-related incident in the ED were identified from the patient-level dataset.
The identification of occurrence of any opioid-related was classified using ICD-10-CM codes
into: (1) opioid abuse, (2) adverse effects of opioids, (3) opioid dependence and unspecified use,
and (4) opioid poisoning. This approach of using ICD codes to categorize any opioid-related
incident has been documented and used in previous studies (More & Barrett, 2017; VivoloKantor et al., 2018; Litaker et al., 2019; Geller et al., 2019; Salzman et al., 2020). Subsequently,
the ICD-10-CM Diagnosis for uncomplicated opioid abuse was recoded as “0” and the ICD-10CM Diagnosis for uncomplicated opioid dependence was recoded as “1”.
Hospital dataset – only the variables of interest were retained in the hospital dataset. These
included, “HOSP_CONTROL” – the control/ownership of hospital, “HOSP_REGION” – the
region of hospital, “HOSP_URCAT4” – the hospital urban-rural designation, and
“TOTAL_EDVisits” – the total number of ED visits from this hospital in the NEDS. A new
variable “PREV_RXOUD_ED” was derived to represent the prevalence of diagnosing and
treating OUD in ED at the hospital level. To determine the prevalence of diagnosing and treating
OUD in the ED at the hospital level, it was assumed that: (1) patients were diagnosed and treated
for OUD at least during one ED visit; (2) the total ED visits – “TOTAL_EDVisits” – for each
hospital represented the total number of times each patient was treated at least once for OUD.
Therefore, the prevalence of diagnosing and treating OUD in the ED at the hospital level
(“PREV_RXOUD_ED”) was calculated by dividing each TOTAL_EDVisits per hospital by the
total number of ED visits for all hospitals for the duration of the study under consideration,
which was 32,680,232 emergency department (ED) visits. In other words, PREV_RXOUD_ED
= TOTAL_EDVisits per hospital/Sum of TOTAL_EDVisits (Woltman et al., 2012).
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“HOSP_ED” – the HCUP ED hospital identifier and “DISCWT” – the weight to ED visits in
AHA universe for each of the cases in the core and hospital datasets were also retained.
The hospital dataset was then merged with the core (patient-level) dataset in a one-to-many
merger using HOSP_ED, the unique identifier common to both the core (patient-level) and
hospital datasets.
State-level policy dataset – the state-level policy dataset was created by abstracting the required
data from the identified sources. Four variables were identified and categorized as “MAT_POL”
– representing the MAT policy status which was coded as “0” when not present and “1” when
present, “MAT_COV” – representing MAT medication coverage status which was coded as “0”
for “No” when not comprehensive and as “1” for “Yes” when comprehensive, “MED_EXP” –
representing Medicaid expansion status which was coded as “0” for “No” when not adopted and
“1” for “Yes” when adopted, and “MED_1115” – representing Medicaid section 1115 behavioral
health waiver status which was coded as “0” for “No” when not approved and “Yes” when
approved.
As part of the data preparation requirements for the statistical analysis, the patient-, and hospitallevel datasets were merged into a single dataset file and the cases in the final dataset file sorted in
ascending order – that is, from lowest to highest value – using HOSP_ED, the unique identifier
common to all individual data files.
Pearson’s chi-squared test was used following cross-tabulation of “nDX_OUD” by the patient
and hospital characteristics to determine if the differences between the diagnosis of opioid abuse
and opioid dependence were statistically significant. Pearson’s chi-squared test was also used
after cross-tabulation of “HOSP_REGION” by the patient and hospital characteristics to
determine if the differences between the regions were statistically significant.
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Statistical analysis – Hierarchical linear models (HLM) (Huta, 2014; Anderson, 2012; Woltman
et al., 2012; Aiken, et al., 2018) were used to estimate the association between the outcome
variable (prevalence) and predictor variables (patient demographic –primary payer, annual
median income, patient location and type of emergency department event – treated & released,
admitted to same hospital, transferred to another or died; and hospital – control/ownership,
region, and designation). HLM was used as the inferential statistical analysis method of choice
for this study because: (1) there were two levels of units in the dataset for this study, i) patients –
were level 1 units because of multiple individual per hospital, and ii) hospitals – were level 2
units because there were multiple hospitals per state in the dataset. As such, the final dataset used
for analysis in this study consisted of 2-level hierarchies. (2) The unweighted sample sizes of the
levels in the hierarchy differed from patient-level (174,061) to hospital-level (953). (3) There
were missing values at the patient-level, the lowest level of the hierarchy, which HLM can
handle. (4) There were no missing data at the hospital-level of the hierarchy thus HLM was more
suitable as there was no need for imputing missing data at this levels before performing HLM
regression. (5) The cases or records at the patient-level were indistinguishable [HLM can be
utilized when cases are distinguishable or not] (Huta, 2014; Anderson, 2012; Woltman et al.,
2012).
Tests of Normality – The outcome variable, PREV_RXOUD_ED, was tested to determine if it
was normally distributed (See Appendix A - Tests of Normality Results). It was not normally
distributed. Therefore, PREV_RXOUD_ED was log transformed to “PREV_RXOUD_ED_Log”
and re-tested for the normality assumption (See Appendix A - Tests of Normality Results). It was
relatively more normally distributed. Additionally, the tests of HLM assumptions using
PREV_RXOUD_ED and PREV_RXOUD_ED_Log revealed more violations of these
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assumptions with PREV_RXOUD_ED than PREV_RXOUD_ED_Log (See Appendix C - HLM
Regression and Test of Assumptions Results). Thus, it was determined to proceed with the HLM
regression analysis using the transformed outcome variable, PREV_RXOUD_ED_Log.
Furthermore, the relationship between outcome variable, PREV_RXOUD_ED_Log and all the
predictor variables was assessed for linearity and was found to be linear.
Missing Data – Little’s Missing Completely at Random (MCAR) Test was performed on the
transformed outcome and predictor variables in the dataset to determine the proportion of
missing data for each variable and how to handle the missing data (See Appendix B - MVA)
(Little & Schenker, 1995). There were no missing data in the transformed outcome variable –
Prevalence (“PREV_RXOUD_ED_Log”). The predictor variables were all categorical as such;
expectation maximization (EM) statistics were not computed. Only patient-level variables –
specifically PAY1, ZIPINC_QRTL, PL_NCHS – had missing data to the proportions of 0.1%,
3.1%, and 1.7% respectively (See Appendix B - MVA). Given the large sample size of this
study, the missing data were not replaced (Allison, 2001; Dong & Peng, 2013).
Test of HLM Assumptions – HLM assumptions were tested for the purposes of this study and no
major violations of these assumptions were found (See Appendix C). Specifically, error or
residual structure and predictor variables assumptions were tested. For this study, error structure
assumptions tested for included ensuring that: patient-level (Level 1) residuals were independent
and normally distributed; hospital-level (Level-2) random effects were independent, multivariate
and normally distributed; and inter level residuals were independent. Predictor variables
assumptions tested for in this study included ensuring that: no multicolinearity exist between
predictor variables and residuals at all levels – that is, patient-level (Level 1) predictor variables
were independent of patient-level residuals and hospital-level (Level-2) predictor variables were
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independent of hospital-level residuals respectively and the predictor variables at the patient-,
and hospital-levels were independent of the random effects at the other levels (Huta, 2014;
Anderson, 2012; Woltman et al., 2012). The statistical analyses for this study was conducted
using IBM SPSS Statistics version 25. All tests of hypotheses were two-tailed with a type-1 error
rate set at 5%.
Human Subjects, Animal Subjects, or Safety Considerations
This study used data from the 2016 Nationwide Emergency Department Sample (NEDS).
The 2016 NEDS is publicly available data developed for the Healthcare Cost and Utilization
Project (HCUP). The HCUP was developed through a Federal-State-Industry partnership
sponsored by the Agency for Healthcare Research and Quality. HCUP data inform decision
making at the national, state, and community levels. There was no need for submission of a
public use file data agreement form to access the dataset. The dataset does not contain personal
identifiers that can be linked back to individual level emergency department visits. The proposal
for this study was reviewed by the University of Texas Health Science Center, School of Public
Health Office of Research. The status of this study was determined by the University of Texas
Health Science Center at Houston Committee for the Protection of Human Subjects to be
exempt. The researcher of this study completed human subject ethics training through the
Collaborative Institutional Training Initiative prior to the commencement of the project.
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RESULTS
A total of 32,680,232 ED visits to 953 hospitals across 35 states and the District of
Columbia which when generalized to the entire United States in 2016 amounted to 144,842,742
visits to the ED in 4,639 hospitals across the 50 states including the District of Columbia were
analyzed in this study. Of these weighted ED visits, 1,623,490 visits were due to opioid-related
incidents.
Descriptive Statistics
The overall prevalence of any opioid-related incident in a U.S. ED observed in the 2016
NEDS was 1.12%. Figure 1 reveals the proportions of the broad categories of opioid-related
incidents that were diagnosed and treated for across the ED in the United States in 2016. Almost
half of these opioid-related incidents were the results of opioid dependence (47.21%). Over 1 in
5 (21.92%) of the incidents were due to opioid abuse. Opioid poisoning constituted just less than
20% while just over 10% of the incidents were because of adverse effects of opioids (Figure 1).
Figure 1. Proportions of the Categories of Any Opioid-Related Incident in U.S. Emergency
Departments
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Proportions of Any Opioid-Related Incident by Category

Opioid
Poisoning,
19.08%

Opioid
Dependence and
Unspecified Use,
47.21%

Opioid Abuse,
21.92%
Adverse Effects
of Opioids,
11.79%

Table 1 details the categories, ICD-10-CM codes, descriptions, frequencies, and
proportions of all opioid-related incidents observed in 2016. There were 132 ICD-10-CM
diagnosis codes identified for any opioid-related incident; 119 (90.15%) of these were observed
in the 2016 NEDS (Table 1). There were preponderant opioid-related incidents diagnosed and
treated in the U.S. ED in 2016. These included: uncomplicated opioid dependence (26.01%);
uncomplicated opioid abuse (20.80%). Opioid dependence with withdrawal (11.35%); initial
encounter with accidental poisoning by heroin (8.37%); initial encounter with adverse effect of
other opioids (6.67%); unspecified, uncomplicated opioid use (5.52%). Initial encounter with
adverse effect of unspecified narcotics (3.54%); initial encounter with accidental poisoning by
other opioids (3.35%). Initial encounter with accidental poisoning by unspecified narcotics
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(2.43%); opioid dependence in remission (1.77%); initial encounter with intentional self-harm
through poisoning by other opioids (1.09%); and initial encounter with adverse effect of
synthetic narcotics (1.00%) (Table 1) (Figure 2).
Table 1. Categories, Descriptions, Frequencies, and Proportions of Any Opioid-Related Incident
Observed in 2016.
Opioid-Related
Incident
Category

ICD-10-CM
Code
F1110
F11120
F11121
F11122
F11129
F1114

Opioid Abuse
(n=13)

F11150
F11151
F11159

Adverse Effects
of Opioids
(n=18)

F11181
F11182
F11188
F1119
T400X5A
T400X5D
T400X5S
T402X5A
T402X5D
T402X5S
T403X5A
T403X5D
T403X5S
T404X5A
T404X5D
T404X5S
T40605A
T40605D
T40605S
T40695A

Opioid
Dependence and
Unspecified Use
(n=29)

T40695D
T40695S
F1120
F1121
F11220
F11221
F11222
F11229
F1123
F1124

Description
Opioid abuse, uncomplicated
Opioid abuse with intoxication, uncomplicated
Opioid abuse with intoxication delirium
Opioid abuse with intoxication with perceptual
disturbance
Opioid abuse with intoxication, unspecified
Opioid abuse with opioid-induced mood disorder
Opioid abuse with opioid-induced psychotic disorder with
delusions
Opioid abuse with opioid-induced psychotic disorder with
hallucinations
Opioid abuse with opioid-induced psychotic disorder,
unspecified
Opioid abuse with opioid-induced sexual dysfunction
Opioid abuse with opioid-induced sleep disorder
Opioid abuse with other opioid-induced disorder
Opioid abuse with unspecified opioid-induced disorder
Adverse effect of opium, initial encounter
Adverse effect of opium, subsequent encounter
Adverse effect of opium, sequela
Adverse effect of other opioids, initial encounter
Adverse effect of other opioids, subsequent encounter
Adverse effect of other opioids, sequela
Adverse effect of methadone, initial encounter
Adverse effect of methadone, subsequent encounter
Adverse effect of methadone, sequela
Adverse effect of synthetic narcotics, initial encounter
Adverse effect of synthetic narcotic, subsequent encounter
Adverse effect of synthetic narcotic, sequela
Adverse effect of unspecified narcotics, initial encounter
Adverse effect of unspecified narcotics, subsequent
encounter
Adverse effect of unspecified narcotics, sequela
Adverse effect of other narcotics initial encounter
Adverse effect of other narcotics, subsequent encounter
Adverse effect of other narcotics, sequela
Opioid dependence, uncomplicated
Opioid dependence, in remission
Opioid dependence with intoxication, uncomplicated
Opioid dependence with intoxication delirium
Opioid dependence with intoxication with perceptual
disturbance
Opioid dependence with intoxication, unspecified
Opioid dependence with withdrawal
Opioid dependence with opioid-induced mood disorder

Frequency
(N=1,623,490)
337,639
2,062
1,023

Proportion
(%)
20.80
0.13
0.06

130
8,614
1,813

0.01
0.53
0.11

130

0.01

242

0.01

483

0.03

0
57
2,270
1,447
3,282
20
18
108,298
325
229
2,923
10
32
16,243
39
43
57,489

0.00
0.00
0.14
0.09
0.20
0.00
0.00
6.67
0.02
0.01
0.18
0.00
0.00
1.00
0.00
0.00
3.54

86

0.01

107
2,215

0.01
0.14

14
0
422,249
28,727
1,214
1,005

0.00
0.00
26.01
1.77
0.07
0.06

171

0.01

3,183
184,301
5,100

0.20
11.35
0.31
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F11250
F11251
F11259
F11281
F11282
F11288
F1129
F1190
F11920
F11921
F11922
F11929
F1193
F1194
F11950
F11951
F11959
F11981
F11982
F11988
F1199
T400X1A
T400X1D
T400X1S
T400X2A

Opioid
Poisoning (n=72)

T400X3A
T400X4A
T400X4D
T400X4S
T400X6A
T401X1A
T401X1D
T401X1S
T401X2A
T401X2D
T401X2S
T401X3A
T401X3S
T401X4A

Opioid dependence with opioid-induced psychotic
disorder with delusions
Opioid dependence with opioid-induced psychotic
disorder with hallucinations
Opioid dependence with opioid-induced psychotic
disorder, unspecified
Opioid dependence with opioid-induced sexual
dysfunction
Opioid dependence with opioid-induced sleep disorder
Opioid dependence with other opioid-induced disorder
Opioid dependence with unspecified opioid-induced
disorder
Opioid use, unspecified, uncomplicated
Opioid use, unspecified, with intoxication, uncomplicated
Opioid use, unspecified, with intoxication delirium
Opioid use, unspecified, with intoxication with perceptual
disturbance
Opioid use, unspecified, with intoxication, unspecified
Opioid use, unspecified with withdrawal
Opioid use, unspecified with opioid-induced mood
disorder
Opioid use, unspecified with opioid-induced psychotic
disorder with delusions
Opioid use, unspecified with opioid-induced psychotic
disorder with hallucinations
Opioid use, unspecified with opioid-induced psychotic
disorder, unspecified
Opioid use, unspecified with opioid-induced sexual
dysfunction
Opioid use, unspecified with opioid-induced sleep
disorder
Opioid use, unspecified with other opioid-induced
disorder
Opioid use, unspecified with unspecified opioid-induced
disorder
Poisoning by opium, accidental (unintentional), initial
encounter
Poisoning by opium, accidental (unintentional),
subsequent encounter
Poisoning by opium, accidental (unintentional), sequela
Poisoning by opium, intentional self-harm, initial
encounter
Poisoning by opium, assault, initial encounter
Poisoning by opium, undetermined, initial encounter
Poisoning by opium, undetermined, subsequent encounter
Poisoning by opium, undetermined, sequela
Underdosing of opium, initial encounter
Poisoning by heroin, accidental (unintentional), initial
encounter
Poisoning by heroin, accidental (unintentional),
subsequent encounter
Poisoning by heroin, accidental (unintentional), sequela
Poisoning by heroin, intentional self-harm, initial
encounter
Poisoning by heroin, intentional self-harm, subsequent
encounter
Poisoning by heroin, intentional self-harm, sequela
Poisoning by heroin, assault, initial encounter
Poisoning by heroin, assault, sequela
Poisoning by heroin, undetermined, initial encounter

124

0.01

331

0.02

506

0.03

0

0.00

197
2,706

0.01
0.17

14,253

0.88

89,635
291
1,465

5.52
0.02
0.09

42

0.00

908
4,037

0.06
0.25

1,197

0.07

45

0.00

234

0.01

364

0.02

0

0.00

126

0.01

704

0.04

3,374

0.21

2,143

0.13

5

0.00

0

0.00

252

0.02

6
274
0
0
174

0.00
0.02
0.00
0.00
0.01

135,963

8.37

194

0.01

137

0.01

6,939

0.43

20

0.00

17
125
4
8,877

0.00
0.01
0.00
0.55
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T401X4D
T401X4S
T402X1A
T402X1D
T402X1S
T402X2A
T402X2D
T402X2S
T402X3A
T402X4A
T402X4D
T402X4S
T402X6A
T402X6D
T403X1A
T403X1D
T403X1S
T403X2A
T403X2D
T403X3A
T403X4A
T403X4D
T403X4S
T403X6A
T404X1A
T404X1D
T404X1S
T404X2A
T404X2D
T404X3A
T404X4A
T404X4D
T404X4S
T404X6A
T40601A
T40601D

Poisoning by heroin, undetermined, subsequent encounter
Poisoning by heroin, undetermined, sequela
Poisoning by other opioids, accidental (unintentional),
initial encounter
Poisoning by other opioids, accidental (unintentional),
subsequent encounter
Poisoning by other opioids, accidental (unintentional),
sequela
Poisoning by other opioids, intentional self-harm, initial
encounter
Poisoning by other opioids, intentional self-harm,
subsequent encounter
Poisoning by other opioids, intentional self-harm
Poisoning by other opioids, assault, initial encounter
Poisoning by other opioids, undetermined, initial
encounter
Poisoning by other opioids, undetermined, subsequent
encounter
Poisoning by other opioids, undetermined, sequela
Underdosing of other opioids, initial encounter
Underdosing of other opioids, subsequent encounter
Poisoning by methadone, accidental (unintentional),
initial encounter
Poisoning by methadone, accidental (unintentional),
subsequent encounter
Poisoning by methadone, accidental (unintentional),
sequela
Poisoning by methadone, intentional self-harm, initial
encounter
Poisoning by methadone, intentional self-harm,
subsequent encounter
Poisoning by methadone, assault, initial encounter
Poisoning by methadone, undetermined, initial encounter
Poisoning by methadone, undetermined, subsequent
encounter
Poisoning by methadone, undetermined, sequela
Underdosing of methadone, initial encounter
Poisoning by synthetic narcotics, accidental
(unintentional), initial encounter
Poisoning by synthetic narcotics, accidental
(unintentional), subsequent encounter
Poisoning by synthetic narcotics, accidental
(unintentional), sequela
Poisoning by other synthetic narcotics, intentional selfharm, initial encounter
Poisoning by other synthetic narcotics, intentional selfharm, subsequent encounter
Poisoning by other synthetic narcotics, assault, initial
encounter
Poisoning by synthetic narcotics, undetermined, initial
encounter
Poisoning by synthetic narcotics, undetermined,
subsequent encounter
Poisoning by synthetic narcotics, undetermined, sequela
Underdosing of other synthetic narcotics, initial encounter
Poisoning by unspecified narcotics, accidental
(unintentional), initial encounter
Poisoning by unspecified narcotics, accidental
(unintentional), subsequent encounter

54
19

0.00
0.00

54,432

3.35

61

0.00

36

0.00

17,689

1.09

38

0.00

9
96

0.00
0.01

4,588

0.28

17

0.00

0
1,757
9

0.00
0.11
0.00

7,013

0.43

15

0.00

13

0.00

1,398

0.09

8

0.00

10
805

0.00
0.05

5

0.00

4
274

0.00
0.02

11,322

0.70

15

0.00

27

0.00

5,859

0.36

27

0.00

54

0.00

791

0.05

0

0.00

4
211

0.00
0.01

39,448

2.43

29

0.00
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T40601S
T40602A
T40602D
T40603A
T40604A
T40604D
T40604S
T40606A
T40691A
T40691D
T40691S
T40692A
T40693A
T40694A
T40694D
T40694S
T40696A
T40696S

Poisoning by unspecified narcotics, accidental
(unintentional), sequela
Poisoning by unspecified narcotics, intentional self-harm,
initial encounter
Poisoning by unspecified narcotics, intentional self-harm,
subsequent encounter
Poisoning by unspecified narcotics, assault, initial
encounter
Poisoning by unspecified narcotics, undetermined, initial
encounter
Poisoning by unspecified narcotics, undetermined,
subsequent encounter
Poisoning by unspecified narcotics, undetermined,
sequela
Underdosing of unspecified narcotics, initial encounter
Poisoning by other narcotics, accidental (unintentional),
initial encounter
Poisoning by other narcotics, accidental (unintentional),
subsequent encounter
Poisoning by other narcotics, accidental (unintentional),
sequela
Poisoning by other narcotics, intentional self-harm, initial
encounter
Poisoning by other narcotics, assault, initial encounter
Poisoning by other narcotics, undetermined, initial
encounter
Poisoning by other narcotics, undetermined, subsequent
encounter
Poisoning by other narcotics, undetermined, sequela
Underdosing of other narcotics, initial encounter
Underdosing of other narcotics, sequela

40

0.00

3,677

0.23

7

0.00

82

0.01

3,185

0.20

8

0.00

5

0.00

85

0.01

1,105

0.07

0

0.00

0

0.00

151

0.01

4

0.00

74

0.00

0

0.00

0
23
5

0.00
0.00
0.00

Note: Total proportions do not add up to 100% because compared to the absolute values; these
relative values were rounded up.
Figure 2. Most Preponderant Opioid-Related Incidents in U.S. Emergency Departments
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2016 Most Preponderant Opioid-Related Incidents in U.S. EDs
Others

8.10%

Initial encounter with adverse effect of synthetic
narcotics

1.00%

Initial encounter with intentional self-harm through
poisoning by other opioids

1.09%

Opioid dependence in remission
Initial encounter with accidental poisoning by
unspecified narcotics

1.77%

2.43%

Initial encounter with accidental poisoning by other
opioids

3.35%

Initial encounter with adverse effect of unspecified
narcotics

3.54%

Unspecified, uncomplicated opioid use

5.52%

Initial encounter with adverse effect of other opioids

6.67%

Initial encounter with accidental poisoning by heroin

8.37%

Opioid dependence with withdrawal

11.35%

Uncomplicated opioid abuse

20.80%

Uncomplicated opioid dependence
0.00%

26.01%
5.00%

10.00% 15.00% 20.00% 25.00% 30.00%

Table 2 summarizes state-level opioid policies of all the 50 states of the United States and
the District of Columbia. Forty-nine states including the District of Columbia (98.0%) had
medication-assisted treatment policies in place for treating opioid use disorder (OUD). Wyoming
(2.0%) was the only state that did not have a medication-assisted treatment policy. Forty states
and the District of Columbia (80.4%) provided comprehensive medication-assisted treatment
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coverage. Ten states (19.6%) comprising Arkansas, Idaho, Kansas, Kentucky, Louisiana,
Nebraska, North Dakota, South Carolina, Tennessee and Wyoming did not provide
comprehensive medication-assisted treatment coverage. Of the 50 states and the District of
Columbia, thirty-seven (72.6%) had expanded Medicaid. The 14 states (27.4%) that had not
expanded Medicaid included Alabama, Florida, Georgia, Kansas, Mississippi, Missouri, North
Carolina, Oklahoma, South Carolina, South Dakota, Tennessee, Texas, Wisconsin, and
Wyoming. In addition, while 31 states (60.8%) had approved Medicaid section 1115 behavioral
health waiver status, twenty (39.2%) consisting of Alabama, Arkansas, Colorado, Connecticut,
District of Colombia, Georgia, Idaho, Iowa, Maine, Mississippi, Missouri, Nevada, North
Dakota, Oklahoma, Oregon, South Carolina, South Dakota, Tennessee, Texas, and Wyoming had
not approved Medicaid section 1115 behavioral health waiver status (Table 2).
Table 2. Characteristics of State-Level Opioid Policies for all 50 States and District of Columbia
Criteria
Medicaid section
MAT
Medicaid
1115 behavioral
medication
expansion
health waiver
State
MAT Policy status
coverage status
status
status
Alabama*
Yes
Yes
No
No
Alaska*
Yes
Yes
Yes
Yes
Arizona

Yes

Yes

Yes

Yes

Arkansas

Yes

No

Yes

No

California

Yes

Yes

Yes

Yes

Colorado*

Yes

Yes

Yes

No

Connecticut

Yes

Yes

Yes

No

Delaware*

Yes

Yes

Yes

Yes

District of
Colombia

Yes

Yes

Yes

No

Florida

Yes

Yes

No

Yes

Georgia

Yes

Yes

No

No

Hawaii

Yes

Yes

Yes

Yes
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Criteria
Medicaid
expansion
status
Yes

Medicaid section
1115 behavioral
health waiver
status
No

State
Idaho*

MAT Policy status
Yes

MAT
medication
coverage status
No

Illinois

Yes

Yes

Yes

Yes

Indiana

Yes

Yes

Yes

Yes

Iowa

Yes

Yes

Yes

No

Kansas

Yes

No

No

Yes

Kentucky

Yes

No

Yes

Yes

Louisiana*

Yes

No

Yes

Yes

Maine

Yes

Yes

Yes

No

Maryland

Yes

Yes

Yes

Yes

Massachusetts

Yes

Yes

Yes

Yes

Michigan*

Yes

Yes

Yes

Yes

Minnesota

Yes

Yes

Yes

Yes

Mississippi

Yes

Yes

No

No

Missouri

Yes

Yes

No

No

Montana

Yes

Yes

Yes

Yes

Nebraska

Yes

No

Yes

Yes

Nevada

Yes

Yes

Yes

No

New Hampshire*

Yes

Yes

Yes

Yes

New Jersey

Yes

Yes

Yes

Yes

New Mexico*

Yes

Yes

Yes

Yes

New York

Yes

Yes

Yes

Yes

North Carolina

Yes

Yes

No

Yes

North Dakota

Yes

No

Yes

No

Ohio

Yes

Yes

Yes

Yes

Oklahoma*

Yes

Yes

No

No

Oregon

Yes

Yes

Yes

No

Pennsylvania*

Yes

Yes

Yes

Yes

Rhode Island

Yes

Yes

Yes

Yes

South Carolina

Yes

No

No

No
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Criteria

MAT Policy status
Yes

MAT
medication
coverage status
Yes

Medicaid
expansion
status
No

Medicaid section
1115 behavioral
health waiver
status
No

Tennessee

Yes

No

No

No

Texas*

Yes

Yes

No

No

Utah

Yes

Yes

Yes

Yes

Vermont

Yes

Yes

Yes

Yes

Virginia*

Yes

Yes

Yes

Yes

Washington*

Yes

Yes

Yes

Yes

West Virginia*

Yes

Yes

Yes

Yes

Wisconsin

Yes

Yes

No

Yes

Wyoming

No

No

No

No

State
South Dakota

Note: * = States not participating in 2016 NEDS; MAT policy status as of September 9, 2019 (present
[Yes]/not present [No]); MAT medication coverage status as of July 1, 2018 (comprehensive [Yes]/noncomprehensive [No]); Medicaid expansion status as of October 9, 2019 (adopted [Yes]/not adopted [No]);
Medicaid section 1115 behavioral health waiver status as of October 9, 2019 (approved [Yes], not
approved [No]).

Table 3 shows the weighted summary statistics of uncomplicated OUD, patient, hospital,
and state-level opioid policy characteristics of the 35 states and the District of Columbia that
contributed to the data analyzed for this study. An estimated 0.5% (759,888/144,842,742) of the
entire patients who visited the ED in the United States in 2016 were diagnosed with and treated
for uncomplicated OUD. Of this less than one per cent, more than half of these patients (55.6%)
were diagnosed with and treated for uncomplicated opioid dependence. The remaining 44.4%
were diagnosed with and treated for uncomplicated opioid abuse (Table 3).
The indicators of financial security for the entire patients diagnosed with and treated for
uncomplicated OUD were largely low with over a third (43.9%) having their treatment paid for
by Medicaid and slightly less than 1 in 4 (24.8%) were covered by Medicare. Only about 12% of
the patients paid out-of-pocket. In addition, more than half of these patients earned an annual
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median income less than $54,000 – just over 1 in 3 (33.8%) earned between $1 and $42,999; and
less than a quarter earned between $43,000 and $53,999. However, over three-quarters (86.6%)
of them resided in metropolitan areas (33.3% in large central metropolitan, 23.9% in large fringe
metropolitan, 21.6% in medium metropolitan, and 7.8% in small metropolitan locations
respectively).
Upon visiting the ED, slightly over half (50.8%) of these patients were treated and released;
47.4% were admitted to the same hospital for further management, and 1.4% were transferred to
another hospital. Less than one per cent (0.1%) of patients with OUD died in the ED.
Less than 1 in 5 of the hospital-owned emergency departments visited by the patients diagnosed
with and treated for OUD were owned by, government (16.6%), private voluntary entities
(16.3%), private not-for-profit organizations (13.3%), and private for-profit establishments
(10.0%) respectively. Over two-thirds of these hospital-owned emergency departments were
located in the southern (35.9%) and midwestern (34.3%) United States respectively. Over 50%
of these hospital-owned emergency departments were located in metropolitan areas. Specifically,
27.5% each in large and small metropolitan areas respectively (Table 3).
Of the 35 states and the District of Columbia analyzed for this study, over three-quarters (77.8%)
provided comprehensive MAT medication coverage. More than 2 in 3 (69.4%) of the states had
adopted Medicaid expansion and over half (58.3%) had approved Medicaid section 1115 waiver
(Table 3).
Table 3. Summary Statistics of OUD, Patient, Hospital, and State-Level Opioid Policy
Characteristics
Frequency
Variable Category/Variables
(N=144,842,742) Proportion
OUD Diagnosis
(n=759,888)
(%)
Opioid abuse
337,639
44.4
Opioid dependence
422,249
55.6
Patient Characteristics
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Primary Payer:
Medicare
Medicaid
Private including HMO
Self-pay
No charge
Other
Annual Median Income ($):
1-42,999
43,000-53,999
54,000-70,999
≥71,000
Patient Location:
Large central metropolitan
Large fringe metropolitan
Medium metropolitan
Small metropolitan
Micropolitan
Not metropolitan or micropolitan
Type of Emergency Department Event:
Treated & released
Admitted to same hospital
Transferred to another hospital
Died
Other (Not admitted in same hospital & discharged alive)
Hospital Characteristics
Control/Ownership:
All [government or private]
Public [government, non-Federal]
Voluntary [private, not-for-profit]
Proprietary [private, investor-owned/for-profit]
Private [private voluntary/proprietary]
Region:
Northeast
Midwest
South
West
Designation:
Large metropolitan area
Small metropolitan area
Micropolitan area
Non-urban residual
Other (Metropolitan [1/2] & Non metropolitan [3/4])
State-level Opioid Policy Characteristics
MAT medication coverage status:

187,853
333,228
118,521
91,999
4,455
21,993

24.8
43.9
15.6
12.1
0.6
2.9

256,209
186,780
160,080
132,315

33.8
24.6
21.1
17.4

252,420
181,384
163,816
59,483
59,506
29,327

33.3
23.9
21.6
7.8
7.8
3.9

385,157
359,988
10,244
897
2,549
(n=4,639)

50.8
47.4
1.4
0.1
0.3
(%)

2,033
770
617
462
758

43.8
16.6
13.3
10.0
16.3

535
1,590
1,665
849

11.5
34.3
35.9
18.3

1,274
1,274
679
1,255
157
(n=36)

27.5
27.5
14.6
27.1
3.4
(%)

73

Non-comprehensive
Comprehensive
Medicaid expansion status:
Not adopted
Adopted
Medicaid section 1115 waiver status:
Not approved
Approved

8
28

22.2
77.8

11
25

30.6
69.4

15
21

41.7
58.3

Note: For OUD Diagnosis, Patient Characteristics, and Type of Emergency Department Event, weighted
n = 759,888. For Hospital Characteristics, weighted n = 4,639. For State-level Opioid Policy
Characteristics, weighted n = 36 (35 States & D.C.). Overall N=144,842,742. Sum of some variable
percentages did not attain 100% because missing values were not included.

Table 4 and Figure 3 display the associated state-level opioid policies by hospital region
of the 35 states and the District of Columbia that contributed to the 2016 NEDS dataset analyzed
in this study. In the northeast region, there were seven states. All of these States in the
northeastern region had MAT policies in place and 100% provided comprehensive MAT
medication coverage. All (100%) of these states had adopted Medicaid expansion while 71.4%
with the exception of Connecticut and Maine had approved the Medicaid section 1115
behavioral health waiver. The Midwest region had 11 states, all of which had existing MAT
policies. However, of these midwestern states, 72.7% excluding Kansas, Nebraska, and North
Dakota, provided comprehensive MAT medication coverage; 63.6% apart from Kansas,
Missouri, South Dakota, and Wisconsin had adopted Medicaid expansion; while 63.6% not
including Iowa, Missouri, North Dakota, and South Dakota had approved the Medicaid section
1115 behavioral health waiver. The south region comprised 10 states. Of these southern states,
all (100%) had MAT policies in place, 60% without Arkansas, Kentucky, South Carolina, and
Tennessee, provided comprehensive MAT medication coverage. While only 40% exclusive of
Florida, Georgia, Mississippi, North Carolina, South Carolina, and Tennessee had expanded
Medicaid; and 40% except for Arkansas, Georgia, Mississippi, South Carolina, Tennessee, and
District of Colombia approved the Medicaid section 1115 behavioral health waiver. Finally, the
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west region consisted of eight states. In these states, 87.5% with the exception of Wyoming had
existing MAT policies, provided comprehensive MAT coverage, and had expanded Medicaid
respectively. The Medicaid section 1115 behavioral health waiver had been approved in 62.5%
of these western regional states apart from Nevada, Oregon, and Wyoming (Table 4) (Figure 3).
Table 4. Descriptive Statistics of the 35 State-Level and District of Columbia Opioid Policies by
Hospital Region
MAT
Medicaid section
MAT
medication Medicaid 1115 behavioral
Hospital
Policy
coverage
expansion
health waiver
Region
States
status
status
status
status
Connecticut
Yes
Yes
Yes
No
Maine
Yes
Yes
Yes
No
Massachusetts
Yes
Yes
Yes
Yes
Northeast
New Jersey
Yes
Yes
Yes
Yes
(n=7)
New York
Yes
Yes
Yes
Yes
Rhode Island
Yes
Yes
Yes
Yes
Vermont
Yes
Yes
Yes
Yes
Illinois
Yes
Yes
Yes
Yes
Indiana
Yes
Yes
Yes
Yes
Iowa
Yes
Yes
Yes
No
Kansas
Yes
No
No
Yes
Minnesota
Yes
Yes
Yes
Yes
Midwest
Missouri
Yes
Yes
No
No
(n=11)
Nebraska
Yes
No
Yes
Yes
North Dakota
Yes
No
Yes
No
Ohio
Yes
Yes
Yes
Yes
South Dakota
Yes
Yes
No
No
Wisconsin
Yes
Yes
No
Yes
Arkansas
Yes
No
Yes
No
District of Colombia
Yes
Yes
Yes
No
Florida
Yes
Yes
No
Yes
Georgia
Yes
Yes
No
No
Kentucky
Yes
No
Yes
Yes
South
(n=10)
Maryland
Yes
Yes
Yes
Yes
Mississippi
Yes
Yes
No
No
North Carolina
Yes
Yes
No
Yes
South Carolina
Yes
No
No
No
Tennessee
Yes
No
No
No
Arizona
Yes
Yes
Yes
Yes
West
California
Yes
Yes
Yes
Yes
(n=8)
Hawaii
Yes
Yes
Yes
Yes
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Montana
Nevada
Oregon
Utah
Wyoming

Yes
Yes
Yes
Yes
No

Yes
Yes
Yes
Yes
No

Yes
Yes
Yes
Yes
No

Yes
No
No
Yes
No

Note: MAT policy status as of September 9, 2019 (present [Yes]/not present [No]); MAT medication
coverage status as of July 1, 2018 (comprehensive [Yes]/non-comprehensive [No]); Medicaid expansion
status as of October 9, 2019 (adopted [Yes]/not adopted [No]); Medicaid section 1115 behavioral health
waiver status as of October 9, 2019 (approved [Yes], not approved [No]).

Figure 3. Overall and Regional Prevalence of State-Level Opioid Policies of the 35 States and
District of Columbia
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Figure 4 represents the overall and regional prevalence of uncomplicated OUD –
comprised of opioid dependence and opioid abuse – diagnosed and treated in U.S. ED in 2016.
Overall, over 5 of every 10 patients who presented at a U.S. ED had uncomplicated opioid
dependence while just over 4 of every 10 patients had uncomplicated opioid abuse. The figure
however showed noteworthy regional differences. The western region of the U.S. revealed that
over 6 of every 10 patients seen in the ED in that region was diagnosed and treated for
76

uncomplicated opioid dependence and just over 3 in 10 of the patients had uncomplicated opioid
abuse. On the other hand, similar to the national average, over 5 of every 10 patients had
uncomplicated opioid dependence and just over 4 of every 10 patients had uncomplicated opioid
abuse in southern U.S. However, in northeastern region of the U.S., approximately 5 of every 10
patients who presented at the ED had uncomplicated opioid dependence or uncomplicated opioid
abuse. Similarly, in midwestern U.S., about 5 of every 10 patients had either uncomplicated
opioid dependence or uncomplicated opioid abuse (Figure 4).
Figure 4. Overall and Regional Prevalence of Uncomplicated OUD Diagnosed and Treated in
U.S. ED in 2016

Overall and Regional Prevalences of OUD
70.00%
64.50%
60.00%
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In Table 5, overall patient and hospital characteristics between all patients diagnosed with
and treated for opioid abuse and opioid dependence in the U.S. ED were compared. There were
significant differences between patients who were diagnosed with and treated for opioid abuse
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and opioid dependence in the ED in all forms of patient and hospital characteristics (p <0.0001).
The following patient characteristics depicted these distinct differences more: among patients
diagnosed with and treated for OUD in the ED, Medicaid paid more for opioid abuse (49.2% vs.
39.8%) while Medicare paid more for opioid dependence (34.6% vs. 12.4%). In addition, the
proportion of self-paying (out-of-pocket payment) patients were higher in those diagnosed with
and treated for opioid abuse (18.2% vs. 7.3%). More patients in the $1-$42,999 annual median
income bracket were diagnosed with and treated for opioid abuse (36.6% vs. 33.5%).
Conversely, more patients in the $43,000-$53,999 annual median income bracket were
diagnosed with and treated for opioid dependence (26.1% vs. 24.6%). There were more patients
diagnosed with and treated for opioid abuse located in metropolitan areas (89.1% vs. 87.3%). In
contrast, more patients diagnosed with and treated for opioid dependence were located in
micropolitan areas (8.5% vs. 7.3%). Concerning the type of ED event that occurred to patients
when they visited the ED, more patients with opioid abuse were treated and released (64.7% vs.
39.6%). On the other hand, the proportion of patients diagnosed with and treated for opioid
dependence who were admitted to the same hospital was more (59.1% vs. 32.8%).
There was a higher proportion of patients with opioid dependence diagnosed with and treated in
hospital-owned ED controlled by private not-for-profit entities (10.3% vs. 8.8%) and private
voluntary organizations (5.0% vs. 3.2%). More patients diagnosed with and treated for opioid
abuse were seen northeastern (30.7% vs. 25.7%) and midwestern (21.5% vs. 16.7%) United
States. On the contrary, more of the patient seen in the southern (31.5% vs. 29.8%) and western
(26.1% vs. 18.0%) regions of the country were diagnosed with and treated for opioid
dependence. Similarly, the proportion of patients diagnosed with and treated for opioid abuse
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seen in hospital-owned ED designation as been located in metropolitan areas was more (88.8%
vs. 87.4%) (Table 5).
Table 5. Weighted Descriptive Statistics of Patient and Hospital Characteristics Comparing
Opioid Abuse and Opioid Dependence
Opioid Abuse
Opioid Dependence
(n=337,639)
(n=422,249)
Variable Category/Variables
Patient Characteristics
Primary Payer:
Medicare
Medicaid
Private including HMO
Self-pay
No charge
Other
Annual Median Income ($):
1-42,999
43,000-53,999
54,000-70,999
≥71,000
Patient Location:
Large central metropolitan
Large fringe metropolitan
Medium metropolitan
Small metropolitan
Micropolitan
Not metropolitan or micropolitan
Type of Emergency Department Event:
Treated & released
Admitted to same hospital
Transferred to another hospital
Died
Other
Hospital Characteristics
Control/Ownership:
All [government or private]
Public [government, non-Federal]
Voluntary [private, not-for-profit]
Proprietary [private, investorowned/for-profit]
Private [private voluntary/proprietary]
Region:
Northeast

Frequency

Proportion
(%)

Frequency

Proportion
(%)

p value
<0.0001

41,777
165,389
53,828
61,086
2,712
11,367

12.4
49.2
16.0
18.2
0.8
3.4

146,076
167,839
64,693
30,913
1,743
10,627

34.6
39.8
15.3
7.3
0.4
2.5

118,746
79,774
70,251
55,972

36.6
24.6
21.6
17.2

137,463
107,006
89,828
76,342

33.5
26.1
21.9
18.6

109,662
84,805
73,892
25,465
24,032
11,778

33.3
25.7
22.4
7.7
7.3
3.6

142,759
96,579
89,924
34,018
35,474
17,550

34.3
23.2
21.6
8.2
8.5
4.2

217,928
110,378
6,123
676
1,479

64.7
32.8
1.8
0.2
0.4

167,229
249,610
4,121
221
1,069

39.6
59.1
1.0
0.1
0.3

272,668
8,784
29,656
14,873

81.0
2.6
8.8
4.4

325,728
12,114
43,561
19,685

77.1
2.9
10.3
4.7

10,604

3.2

21,161

5.0

<0.0001

<0.0001

<0.0001

<0.0001
103,397

30.7

108,457

25.7
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Midwest
South
West
Designation:
Large metropolitan area
Small metropolitan area
Micropolitan area
Non-urban residual
Other (Metropolitan [1/2] & Non
metropolitan [3/4])

72,449
100,152
60,588

21.5
29.8
18.0

70,449
133,196
110,147

16.7
31.5
26.1

193,179
105,635
18,553
5,800
13,449

57.4
31.4
5.5
1.7
4.0

237,509
131,767
28,057
8,387
16,531

56.2
31.2
6.6
2.0
3.9

<0.0001

Note: For Patient Characteristics, Type of Emergency Department Event and Hospital Characteristics,
weighted n = 759,888. Overall N=144,842,742. Sum of some variable percentages did not attain 100%
because missing values were not included.

Table 6 presents the weighted summary statistics of uncomplicated OUD diagnosis,
patient and hospital characteristics by hospital region. In all the four hospital regions, there were
significant differences in patient and hospital characteristics (p <0.0001). Specifically, the
diagnoses of uncomplicated opioid dependence were more preponderant in the western (64.5%),
southern (57.1%), and northeastern (52.2%) regions. Uncomplicated opioid abuse was the
predominant diagnosis in the midwestern region at 50.7%. Patient characteristics that exhibited
these unique regional differences included: primary payers of diagnosing and treating OUD in
the ED – where in spite of Medicaid being the predominant payer across all the regions, an
additional more than 1 in 5 patients were self- (or out-of-pocket) paying in the southern region
compared to the less than 1 in 10 self-paying patients in the other regions. Annual median
income revealed that patients in the $1-$53,999 income bracket were mainly in the southern
(72%), midwestern (57%), and western (54%) regions. The northeastern region comprised
patients mostly in the $54,000 and higher income bracket (52.5%). Patient location showed that
over 1 in 10 patients resided in micropolitan areas in the midwestern region compared to other
regions in addition to the fact that most patients across all regions were overwhelmingly
metropolitan area dwellers. Over half of the patients presenting to ED in the northeastern and
midwestern regions respectively were treated and released while about 1 in 2 of the patients seen
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in ED in the southern and western regions were admitted to the same hospital of the ED to which
they presented. Regional differences were more pronounced in the following hospital
characteristics: hospitals’ urban-rural designation revealed that just over 10% of hospitals with
ED were designated as micropolitan in the midwestern region compared to other regions. This is
in addition to the overwhelming metropolitan designation of all hospitals across all the regions
(Table 6).
Table 6. Weighted Summary Statistics of Opioid Use Disorder Diagnosis, Patient and Hospital
Characteristics by Hospital Region
Variable Category/
Variables
OUD Diagnosis
Opioid abuse
Opioid dependence

Northeast Region
(n=211,854)
Frequency
(%)

Midwest Region
(n=142,898)
Frequency
(%)

South Region
(n=233,348)
Frequency
(%)

West Region
(n=170,735)
Frequency
(%)

103,397
108,457

48.8
51.2

72,449
70,449

50.7
49.3

100,152
133,196

42.9
57.1

60,588
110,147

35.5
64.5

39,275

18.5

33,597

23.6

62,178

26.7

52,803

31.0

117,281

55.4

66,811

46.8

73,498

31.5

75,638

44.4

Private including HMO

33,451

15.8

22,568

15.8

35,168

15.1

27,333

16.0

Self-pay

15,895

7.5

14,007

9.8

52,247

22.4

9,849

5.8

No charge

1,140

0.5

714

0.5

2,490

1.1

111

0.1

Other

4,704

2.2

4,956

3.5

7,639

3.3

4,695

2.8

Patient Characteristics
Primary Payer:
Medicare
Medicaid

Annual Median Income ($):
1-42,999

<0.0001

59,219

28.8

53,589

38.0

100,793

44.4

42,608

26.3

43,000-53,999

38,442

18.7

40,908

29.0

62,582

27.6

44,849

27.7

54,000-70,999

51,150

24.9

28,742

20.4

42,668

18.8

37,520

23.2

≥71,000

56,601

27.6

17,877

12.7

20,989

9.2

36,848

22.8

Patient Location:
Large central metropolitan

56,585

27.3

49,281

34.6

65,989

28.6

80,564

48.6

Large fringe metropolitan

80,168

38.7

28,183

19.8

58,503

25.4

14,530

8.8

Medium metropolitan

45,017

21.7

24,076

16.9

53,234

23.1

41,489

25.0

Small metropolitan

11,529

5.6

15,819

11.1

19,072

8.3

13,063

7.9

9,409

4.5

17,954

12.6

19,111

8.3

13,033

7.9

4,334

2.1

7,133

5.0

14,813

6.4

3,047

1.8

117,465

55.4

74,526

52.2

109,366

46.9

83,800

49.1

89,405

42.2

64,813

45.4

120,707

51.7

85,064

49.8

3,334

1.6

2,276

1.6

2,920

1.3

1,714

1.0

405

0.2

191

0.1

214

0.1

87

0.1

1,245

0.6

1,093

0.8

140

0.1

71

0.0

211,854

100.0

124,075

86.8

153,118

65.6

109,349

64.0

Micropolitan
Not
metropolitan/micropolitan
Type of ED Event:
Treated & released
Admitted to same hospital
Transferred to another
hospital
Died
Other
Hospital Characteristics
Control/Ownership:
All [government or private]

p value
<0.0001

<0.0001

<0.0001

<0.0001
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Public [government, nonFederal]
Voluntary [private, not-forprofit]
Proprietary [private,
investor-owned/for-profit]
Private [private
voluntary/proprietary]

0

0.0

4,194

2.9

11,845

5.1

4,859

2.8

0

0.0

0

0.0

49,122

21.1

24,096

14.1

0

0.0

0

0.0

19,262

8.3

15,296

9.0

0

0.0

14,629

10.2

0

0.0

17,136

10.0

Designation:
Large metropolitan area

137,704

65.0

79,320

55.5

131,908

56.5

81,756

47.9

Small metropolitan area

<0.0001
58,872

27.8

44,003

30.8

78,568

33.7

55,959

32.8

Micropolitan area

8,412

4.0

15,599

10.9

13,693

5.9

8,905

5.2

Non-urban residual
Other (Metropolitan [1/2] &
Nonmetropolitan [3/4])

3,155

1.5

3,224

2.3

6,166

2.6

1,642

1.0

3,711

1.8

752

0.5

3,014

1.3

22,472

13.2

Note: For Patient Characteristics and Hospital Characteristics, weighted n = 759,888. Sum of some
variable percentages did not attain 100% because missing values were not included.

Tests of HLM Assumptions Results
The collinearity statistics revealed no multicollinearity between the predictor variables.
This is confirmed by the tolerance for each of the predictor variable in models 1 to 2 shown to be
greater than 1-R2 (i.e. >0.746); and the variance inflation factor (VIF) for each of the predictor
variable in models 1 to 2 was less than 10 (See Appendix C - Coefficients). In addition, the
points on the normal probability-probability plot are close to and follow the line (multivariate
normality); the scatter plot showed relatively scattered dots which were mostly between -3 and
+3 on both axes indicating that the errors of the data in this study were normally distributed and
the variance of the residuals were constant (homoscedasticity) (See Appendix C – Normal P-P
Plot and Scatterplot). Furthermore, the maximum value of the Cook’s Distance – a measure of
influential outliers within the predictor variables – was 0.001 (normal <1) which indicated that
there was no influential value within the predictor variables that could have negatively affected
models 1 to 2 of the HLM. The minimum and maximum values of the standard residuals were
expected to be between -3 to +3. In this study, the minimum was -7.446 which was far from -3,
however, the maximum value was not too far form +3 at +3.900 (See Appendix C – Residual
Statistics).
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HLM Regression Results
In the model 1 of the HLM regression, patient-level characteristics comprising OUD
diagnosis, primary payer, annual median income, patient location, and type of ED event
accounted for a significant 15.6% of the variance in prevalence of patients diagnosed with and
treated for OUD in the ED (R2=0.156, Adjusted R2=0.156, F(5,734621)=27245.686, p<0.0001).
When the hospital-level characteristics consisting of control/ownership of hospital, region of
hospital, and hospital urban-rural designation were entered in model 2, they accounted for an
additional and significant 9.7% of the variance in prevalence of patients diagnosed with and
treated for OUD in the ED (R2 change=0.097, F(3,734618)=31937.906, p<0.0001). Combined,
all 8 predictor variables – OUD diagnosis, primary payer, annual median income, patient
location, type of ED event, control/ownership of hospital, region of hospital, and hospital urbanrural designation – accounted for a significant 25.4% of the variance in prevalence of patients
diagnosed with and treated for OUD in the ED (R2=0.254, Adjusted R2=0.254, F change
(3,734618)=31937.906, p<0.0001). Overall, the patient- and hospital-level predictor variables all
accounted for a significant proportion of unique variance in the final regression model
(Appendix C – Model Summary).
In model 2, the final HLM regression, the ranking of each of the 8 predictor variables
based on the proportion of the variance accounted for in the prevalence of patients diagnosed
with and treated for OUD in the ED was reported. These include, control/ownership of hospital
(9.672%), patient location (6.350%), annual median income (1.440%), hospital designation
(1.210%), OUD diagnosis (0.202%), primary payer (0.040%), region of hospital (0.025%), ED
event (0.008%) (Table 7) (Figure 5).
Table 7. Unstandardized Coefficients, Standardized Coefficients, and Proportion of Variance
Accounted for by each Predictor Variable in the Hierarchical Linear Models
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Regression Models/
Std. Error
Predictor Variables
B (95%CI)
B
β
p value
sr2
Model 1
OUD diagnosis
0.017(0.016,0.019)
0.001
0.026 <0.0001
0.001
Primary payer
0.006(0.005,0.007)
0.000
-0.021 <0.0001
0.000
Annual median income
-0.028(-0.028,-0.027)
0.000
-0.094 <0.0001
0.010
Patient location
-0.092(-0.093,-0.092)
0.000
-0.399 <0.0001
0.155
ED event
0.000(0.000,0.000)
0.000
-0.006 <0.0001
0.000
Model 2
OUD diagnosis
0.027(0.026, 0.028)
0.001
0.040 <0.0001
0.002
Primary payer
0.005(0.004,0.006)
0.000
0.018 <0.0001
0.000
Annual median income
-0.031(-0.032,-0.031)
0.000
-0.106 <0.0001
0.014
Patient location
<0.0001
-0.060(-0.061,-0.060)
0.000
-0.259
0.063
ED event
0.251
0.000(-0.001,0.000)
0.000
-0.008
0.000
Control/ownership of
-0.096(-0.096,-0.095)
0.000
-0.320 <0.0001
0.096
hospital
Region of hospital
0.005(0.004,0.005)
0.000
0.016 <0.0001
0.000
Hospital designation
-0.023(-0.024,-0.023)
0.000
-0.105 <0.0001
0.012
Note: B=unstandardized coefficient, CI=confidence interval, β=standardized coefficient
(indicates the contribution of each predictor variable to the prevalence of treating OUD in the
ED); sr2=squared semi-partial correlation (indicates proportion of unique variance in prevalence
of treating OUD in the ED accounted for by each predictor variable).
Figure 5. Ranking of Predictor Variables by their Percentage Influence on Variance of the
Prevalence of Treating OUD in the ED
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DISCUSSION
The overall prevalence of any opioid-related incident diagnosed and treated the U.S. ED
was 1.12%. This represents a greater than 900% increase in similar visits since 1999 (Salzman et
al., 2020) and an increase of over 1,000% since 2004 (Xie et al, 2014). Over two-thirds of the
patients who presented at U.S. ED in 2016 with any opioid-related incident were diagnosed and
treated for OUD. Specifically, uncomplicated OUD accounted for almost half of these cases. It is
important however to note that these numbers may have been overestimated since there may
have been multiple visits to the ED and multiple diagnosis for any given patient. Nevertheless,
uncomplicated OUD – comprising uncomplicated opioid dependence and uncomplicated opioid
abuse – was the most prevalent opioid-related incident in 2016 compared to accidental opioid
poisoning, adverse effect of opioids or intentional opioid poisoning. The implications of this
finding is that interventions targeted at adequately addressing OUD may potentially reduce the
burden of the opioid crisis by more than 50%.
The overall prevalence in this study of ED visits in the entire United States resulting in
the diagnosis and treatment of uncomplicated OUD was 0.5%. Of these, an estimated fifty-six
per cent or more than 1 in 2 of the patients who visited the ED had uncomplicated opioid
dependence. This is in spite of 98% of States in the U.S having functional opioid treatment
centers, 80.4% of which deliver comprehensive medication-assisted treatment (MAT) with this
MAT administered in 72.6% of States that have expanded Medicaid and 60.8% that have
approved Medicaid section 1115 behavioral health waiver (Kaiser Family Foundation, 2019;
SAMHSA, 2015, 2019).
Generally, the patients with uncomplicated OUD who visited the hospital-owned ED
were mostly of low-income status, metropolitan areas residents, covered by Medicaid, and
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treated and released from the ED. These hospital-owned ED were majorly, controlled by the
government and privately-owned voluntary organizations, in metropolitan areas, and in the
Southern and Midwestern United States. Notwithstanding the general characterization of the
patients with uncomplicated OUD and the hospitals that they presented, there were significant
patient-, hospital-, and state-policy level differences between uncomplicated opioid dependence
and uncomplicated opioid abuse. Additionally, significant regional differences were noted for all
uncomplicated OUD diagnosis and across all categories of patient-, hospital-, and state-level
policy characteristics.
From a diagnosis perspective, the patients with uncomplicated opioid dependence were
preponderantly upper-lower income class, micropolitan residents, covered by Medicare, admitted
to the same hospital as ED to which they presented; and attended to largely in hospital-owned
ED that were privately-owned not-for-profit entities, in micropolitan areas, and in the Southern
and Western U.S. On the other hand, patients with uncomplicated opioid abuse were
predominantly of lower-lower income status, metropolitan dwellers, Medicaid covered; and
presented commonly to privately-owned not-for-profit organizations (though less in proportion
than opioid dependence case), in metropolitan locations, and in the Northeastern and Midwestern
United States.
Regionally, however, the relationship between patient-, hospital-, and state-level policy
characteristics have not been studied in great detail prior to this study. In the northeastern U.S.
where all the states in this study had MAT policies, comprehensive MAT medication coverage,
adopted Medicaid expansion, and more than two-thirds approved Medicaid section 1115
behavioral health waiver, uncomplicated opioid dependence was the main diagnosis. However, it
was surprising that more of the patients who were in the higher income bracket, still had
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Medicaid as their predominant insurer and were mostly treated and released from the ED after
their uncomplicated OUD diagnosis. In the midwestern region, however, with all states in this
study having existing MAT policies but with less than three-quarters providing comprehensive
MAT medication coverage and less than two-thirds haven adopted Medicaid expansion and
Medicaid section 1115 behavioral health waiver respectively, uncomplicated opioid abuse was
the predominant diagnosis. It was not surprising that the patients who were mostly low income
and had Medicaid as their primary payer were typically treated and released post-uncomplicated
OUD diagnosis in the ED. In contrast, states in the southern region of this study, all of which
have MAT policies in place but with less than two-thirds providing comprehensive MAT
medication coverage and just over one-third haven expanded Medicaid and approved the
Medicaid section 1115 behavioral health waiver respectively, a diagnosis of uncomplicated
opioid dependence was more preponderant. It was thus not surprising that the patients diagnosed
and treated for OUD in this region though in the lower income bracket, had the highest
proportion of self-paying patients and lowest proportion of Medicaid paying patients of all the
regions. In addition, they were mostly admitted to the same hospital as the ED they were seen.
Lastly, within the western U.S. in this study, where more than four-fifths had MAT policies,
comprehensive MAT medication coverage, adopted Medicaid expansion respectively, and just
less than two-thirds approved Medicaid section 1115 behavioral health waiver, uncomplicated
opioid dependence was the highest diagnosis of all the regions. It was interesting that the
proportion of patients in both the lower and higher income brackets was almost evenly split.
Similarly in this western region of the U.S., about the same number of those patients that were
treated/released were admitted following the diagnosis of OUD.
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To our knowledge, this is the first study to show the significant cumulative and individual
effects of patient-level and hospital-level characteristics on the prevalence of diagnosing and
treating OUD in the ED in the United States. Specifically, no previous work has attempted to
highlight the relationship between state-level policy and patient/hospital-level characteristics
regarding diagnosing and treating OUD in the ED. Prior research, even those that used datasets
similar to this study, focused on patient-level only, hospital-level only or a combination of
patient- and hospital-level factors only (Wu et al., 2016; Peterson et al., 2018; Hadland et al.,
2017; Mosher et al., 2017; Gaither et al., 2016; Xie et al., 2014; Chandwani et al., 2013; Mejia et
al., 2018; Upadhyay et al., 2018; Rivera et al., 2017; Singh et al., 2016; Wall et al., 2015; Wang
et al., 2015). Additionally, findings from this study revealed over 1,000% increase in the total
number of ED visits associated with nonmedical use of opioids in the United States between a
12-year period from 2004 to 2016 (Xie et al, 2014). Also, this study supports the findings of
prior studies that showed that in spite of enacted state-level policies to address the opioid crisis
(Blackman, 2017; National Alliance for Model State Drug Laws, 2017; Kaiser Family
Foundation, 2019; SAMHSA, 2015, 2019), geographic, regional, and other factors still account
for the rising numbers of patients with OUD visiting the ED (Martin et al., 2016). In addition,
this study revealed that state-level policies such as the decision by a state to adopt Medicaid
expansion, hospital-level factor such as the control and ownership of the hospital and its ED, and
patient-level factor such as where patients are located play more significant roles in determining
the prevalence of diagnosing and treating OUD in the United States than patient-level
characteristics like the specific OUD diagnosis or primary payer of the OUD treatment. This may
be due to issues related to access to and cost of caring for patients with OUD because those who
really need the care cannot access or pay for it. Furthermore, to avoid the ecological fallacy of
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using group-level (in this study, hospital-level) findings to make individual-level (in this study,
patient-level) inferences or its opposite of using individual-level results to inform group-level
decision making – the atomistic fallacy, a multi-faceted approach needs to be adopted in
addressing the current opioid crisis. This is demonstrated in this study wherein factors at
different levels were assessed for their individual influences on the prevalence of diagnosing and
treating OUD in the ED.
Unlike prior studies (Chandwani et al., 2013; Mejia et al., 2018; Upadhyay et al., 2018;
Rivera et al., 2017; Singh et al., 2016; Wall et al., 2015; Wang et al., 2015) however, that
considered age, gender, and race/ethnicity as contributing factors to the treatment of their
conditions of interest in the ED, this study did not want to duplicate such works. Thus, only
patient-level variables – such as primary payer, annual median income, and patient location –
that could be aggregated to higher levels such as the hospital-level were utilized. This approach
of aggregating data for use at different levels has been used in previous research (Aiken, et al.,
2018; Wright, et al., 2014; McHugh & Stimpfel, 2012; Claxton, et al., 2015; AHRQ, 2017).
Similar to previous literature, this study’s findings revealed that total admissions for treatment of
OUD increased in 2016 (SAMHSA, 2014, 2017, 2018). In addition, however, our study was able
to provide previously unavailable information about the type of OUD majorly responsible for
this increase. Our findings indicated that opioid dependence (59.1%) was more significantly
responsible than opioid abuse (32.8%) for this increase in total admissions for OUD treatment.
We were also able to show that significantly more patients with opioid abuse (64.7%) than with
opioid dependence (39.6%) were treated and released from the ED.
The very low prevalence of diagnosing and treating uncomplicated OUD in the ED in the
U.S. revealed in this study may be due to patient-related factors – such as fear of stigmatization
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and reprisals by healthcare workers thus patients with OUD do not present in the ED (Martin et
al., 2016); provider-related factors – consisting of lack of adequate knowledge, skills, and
training necessary to treat OUD in the ED (Rubin, 2019; Yang, et al., 2018; Ho & Argáez, 2018;
Knudsen et al., 2011); system-related factors – including lack of sufficient ED with capabilities
and resources to treat OUD (Martin et al., 2016), negative attitude and perception of law
enforcement and the judiciary about patients with OUD leading to incarceration rather than
assistance; and policy-related factors – comprising dearth of policies for mandating education
and training for providers to treat OUD, poor reimbursement policies for screening, risk
assessment, and treatment of OUD particularly in the ED (Martin et al., 2016). The findings in
this study that public insurance through Medicare and Medicaid were predominantly responsible
for paying for OUD treatment followed by private insurance entities then self-paying patient
aligns with the findings in previous research (Mark et al, 2005; SAMHSA, 2013c). This trend is
projected to continue in the future with Medicaid playing an increasingly significant role as the
primary payer for OUD treatment due to continuous expansion and enrollment in Medicaid
(SAMHSA, 2014a).
In addition, this study revealed that patients with OUD irrespective of whether the
specific diagnosis was opioid dependence or opioid abuse presented more at hospital-owned ED
that were privately owned not-for-profit organizations. Perhaps, these voluntarily controlled
private ED provide better access to and quality of care including shorter wait times brought
about by better funding compared to publicly or government-controlled ED thus the attraction
for patients with OUD. Regarding paying for OUD treatment, it is plausible that Medicaid was
the major primary payer for patients with opioid abuse because these patients were usually
younger than 65 years old (SAMHSA, 2010). However, for those patients less than 65 years who
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did not initiate and/or complete treatment early and aged older than 65 years, Medicare then took
over paying the cost of their care by which time they may have become opioid dependent.
Generally, the geographical variations and low markers of financial stability associated with
patients having OUD highlighted in previous studies (Keyes et al., 2014; Ghertner & Groves,
2018; Karamouzian & Kerr, 2018; Davenport & Matthews, 2018) have persisted in this study
findings. However, concerning the relationships between state-level policy, hospital regional and
socioeconomic characteristics, this study was able to provide new and more detailed information
described above.
Strengths and Limitations
In addition to the conceptualization- and finding-specific strengths highlighted above,
there are methodological strengths to this study. First, this study utilizes a nationally
representative dataset – the Nationwide Emergency Department Sample (NEDS) including
children and adults. Second, this study provides most current estimates. Third, due to the size of
the dataset, it provides accurate estimates to guide policy and decision-making. Fourth, use of
hospital-based population allows for focus on specific population of interest and targeting of
potential interventions (Setia, 2016). Fifth, there is reduction of type I error with the use of HLM
because HLM bases the sample size it uses for its inferential statistical analysis on the group
numbers and not the total number of cases. Finally, using HLM allows for separation of within
group from between-group effects.
Limitations – NEDS only collected data from noninstitutionalized civilian US population.
As such, non-civilian and institutionalized population are not included. Therefore,
generalizability of the findings in this study is limited to noninstitutionalized civilian U.S.
population only. Second, not all 50 states contributed to the 2016 NEDS, thus only policies
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specifically within the 35 states of the U.S. and the District of Columbia contributing to the 2016
NEDS were used in the analysis for this study. Third, the dataset has limited patient variables
thus restricting the robustness of the analysis. Fourth, generally, HLM is conservative when
testing level 1 (in this study, patient-level) relationships thus has less power than using the
generalized linear regression. However, the large sample size in this study addressed this
limitation.
Policy Implications
All stakeholders particularly policy makers at the state-level need to continuously
evaluate state-level policies and their impact on prevalence of diagnosing and treating OUD in
the ED. In addition, there is need for continuous monitoring and evaluation of opioid treatment
programs (OTP) in order to determine their usability and usefulness. Furthermore, there should
be more funding of hospital-owned ED treatment of OUD (Carney, 2019; Miller, 2019). More
importantly there is the need for State lawmakers to expedite current multi-sectoral efforts at
developing novel policies to remedy the crisis (Petruzzelli, 2019). Innovative policies to consider
include: encouraging alternative approaches such as the emerging non-medication or
complementary modalities of pain management for patients simultaneously receiving OUD
treatment (White, 2018; Barry, et al., 2012), expanding ED-based MAT programs (Carney, 2019;
Miller, 2019), and developing creative reimbursement contracts with stand-alone
Urgent/Emergency Care Centers to treat OUD. These have become necessary because it is
possible that more patients with OUD visit other establishments other than the ED to receive
treatment.
Health Information Technology Management Practice Implications
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Regarding health information technology management, there are opportunities for
creating policies on interoperability and best practices for information sharing (Center for
Connected Health Policy, 2018). In addition, there are opportunities for using novel approaches
such as telehealth for caring for patients with OUD since use of telemedicine has been piloted
and shown to be promising (Rubin, 2019; Yang, et al., 2018; Ho & Argáez, 2018). These are
imperative because the diagnosis and treatment prevalence of OUD in the ED maybe the result
of hospitals and their ED still operating in individual silos, not communicating, being
inaccessible due to their locations or lacking trained healthcare workers capable of prescribing
for and treating OUD (Rubin, 2019; Yang, et al., 2018; Ho & Argáez, 2018; Knudsen et al.,
2011). Finally, policies related to using these emerging types of care delivery modalities and
reimbursement for OUD treatment are required (Centers for Medicare and Medicaid Services,
2019; Savage, 2019).
Future Research Directions
In the future, this OUD research will be expanded by creating dose-response models to
capture incremental effects of varied OUD severity on prevalence of OUD diagnosed and treated
in the ED. Additionally, the prevalence of OUD among the current study population will be
quantified to determine potentially preventable cases of OUD by using targeted interventions to
effectively address the opioid crisis. Furthermore, I will like to examine the association between
patient, hospital, and state-level policy factors and actual cost (not charges) of caring for
individuals with OUD in the ED. In addition, I will also want to evaluate through comparative
analysis whether using MAT to provide treatment for individuals diagnosed with OUD is still
cost effective and if not, what other approaches may be more cost effective.
Key Messages
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•

There was more than 1,000% increase in opioid-related incident visits from 144, 600 to
1,623,490 visits to the emergency departments (ED) in the United States (U.S.) between
2004 and 2016.

•

There was a 32% increase in ICD-10-CM Diagnostic Codes for opioid-related incidents
identified in the 2016 NEDS.

•

Uncomplicated opioid use disorder (OUD) – comprising uncomplicated opioid
dependence and uncomplicated opioid abuse constituted approximately 69% of any
opioid-related incident ED visit in 2016.

•

Uncomplicated opioid dependence was the more prevalent reason patients with any
opioid-related incident visited the ED in 2016.

•

More than 1 in 4 patients with uncomplicated opioid dependence were treated in U.S. ED
in 2016 compared to about 1 in 5 patients with uncomplicated opioid abuse.

•

Targeted interventions at addressing uncomplicated OUD may have potentially reduced
the opioid crisis by about 50% in 2016.

•

Significant regional disparities still exist between patient-, hospital-, and state-policy
level characteristics influencing diagnosis and treatment of OUD in U.S. ED. This is in
spite of existing efforts aimed at addressing the opioid crisis.

•

Socioecological rather than discriminatory and punitive approaches may be required to
understanding and addressing the opioid crisis.

•

Comprehensive data collected, aggregated, and analyzed at the individual (patient)-level
and group (interpersonal, organizational, community/environmental, and societal/policy)level can potentially improve understanding of factors influencing the current opioid
crisis.
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•

Continuous quality monitoring, evaluation, and improvement of existing opioid crisisrelated policies are necessary but not sufficient to contain the current opioid crisis, which
is constantly evolving.

•

High quality data-driven innovative policy creation, decision-making, and resource
allocation are critical to effectively addressing the current opioid crisis.
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CONCLUSIONS
The prevalence of diagnosing and treating opioid use disorder in the emergency
departments in the United States is very low. This is in spite of the significant rise in the total
number of ED visits attributable to nonmedical use of opioids in the United States. Overall, a
combination of patient-level, hospital-level, and state-level policy characteristics can potentially
significantly influence the prevalence of diagnosing and treating opioid use disorder in the
emergency departments. However, studied individually, hospital-level characteristics more than
patient-level characteristics contributed significantly to explaining the variance in the low
prevalence of caring for opioid use disorder in the emergency departments.
As such, in addressing the current opioid crisis, a socioecological approach may be
required such that all levels contributing to this crisis are purposefully and simultaneously
targeted discretely and in combination. Specifically, individual and group-level factors such as
interpersonal, organizational, community/environmental and societal characteristics should be
considered. This ought to be performed with the view to developing innovative policies and
programs that can positively and significantly address this present opioid crisis. All of these
efforts should be occurring while existing policies and programs are continuously monitored and
evaluated for clinical efficiency, cost-effectiveness, quality, and public health impact.
Approaching the opioid crisis in this manner while not guaranteeing more effective
decision-making, judicious allocation of scarce resources, and elimination of waste, will almost
certainly ensure an integrated and holistic method to addressing the crisis.
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APPENDICES
APPENDIX A: Tests of Normality Results
For PREV_RXOUD_ED:

Case Processing Summary
Cases
Valid
N
Prevalence of treating OUD in

Missing
Percent

758835

N

Total

Percent

100.0%

0

N

0.0%

Percent

758835

100.0%

ED at hospital level

Descriptives
Statistic

Std. Error

Prevalence of treating OUD in

Mean

.002623987740

ED at hospital level

95% Confidence Interval for

Lower Bound

.002617792160

Mean

Upper Bound

.002630183310

5% Trimmed Mean

.002205758840

Median

.001958003240

Variance

.0000031610619

.000

Std. Deviation

.0027536373300

Minimum

.0000106180

Maximum

.0175897160

Range

.0175790980

Interquartile Range

.0017821477

Skewness

3.941

.003

Kurtosis

18.011

.006

Tests of Normality
Kolmogorov-Smirnova
Statistic
Prevalence of treating OUD in ED at hospital level

df
.212

Sig.
758835

.000

a. Lilliefors Significance Correction
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For PREV_RXOUD_Log:
Case Processing Summary
Cases
Valid

Missing

N
PREV_RXOUD_ED_Log

Percent

758835

N

Total

Percent

100.0%

0

0.0%

N
758835

Percent
100.0%

Descriptives
Statistic
PREV_RXOUD_ED_Log

Mean

-2.7133

95% Confidence Interval for

Lower Bound

-2.7141

Mean

Upper Bound

-2.7126

5% Trimmed Mean

-2.7137

Median

-2.7082

Variance

Std. Error
.00038

.110

Std. Deviation

.33099

Minimum

-4.97

Maximum

-1.75

Range

3.22

Interquartile Range

.39

Skewness

-.125

.003

Kurtosis

2.041

.006

Tests of Normality
Kolmogorov-Smirnova
Statistic
PREV_RXOUD_ED_Log

.067

df
758835

Sig.
.000

a. Lilliefors Significance Correction
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APPENDIX B: Little’s Missing Completely at Random (MCAR) Test Results

MVA
Univariate Statistics
No. of Extremesa

Missing
N
PREV_RXOUD_ED_Log

663906

nDX_OUD

Mean

Std. Deviation

-2.7173

.32974

Count

Percent

Low

0

.0

663906

0

.0

PAY1

663230

676

.1

ZIPINC_QRTL

643396

20510

3.1

PL_NCHS

652536

11370

1.7

EDEVENT

663906

0

.0

HOSP_CONTROL

663906

0

.0

HOSP_REGION

663906

0

.0

HOSP_URCAT4

663906

0

.0

High

3767

6406

a. Number of cases outside the range (Mean - 2*SD, Mean + 2*SD).

EM Estimated Statistics

EM Meansa
PREV_RXOUD_ED_Log
-2.7180
a. Little's MCAR test: Chi-Square = 5.434, DF = 1, Sig. = .020
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APPENDIX C: Hierarchical Linear Model (HLM) Regression and Test of Assumptions Results
The Hierarchical Linear Model (HLM) regression and test of assumptions results are shown
below.

Descriptive Statistics
Mean
Log Transformation of outcome variable PREV_RXOUD_ED

Std. Deviation

N

-2.7140

.33005

734627

String to numeric recode of OUD

.56

.497

734627

Primary expected payer (uniform)

2.28

1.148

734627

Median household income national quartile for patient ZIP Code

2.23

1.111

734627

Patient Location: NCHS Urban-Rural Code

2.43

1.423

734627

Type of ED Event

1.84

5.611

734627

.52

1.103

734627

Region of hospital

2.47

1.117

734627

Hospital urban-rural designation

1.78

1.478

734627

Control/ownership of hospital
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Correlations
Median
household

Pearson

Log Transformation of

Correlation

outcome variable

income

Patient

String to

Primary

national

Location:

Log Transformation of

numeric

expected

quartile for

NCHS

outcome variable

recode of

payer

patient ZIP

Urban-

Type of ED

Control/ownership of

Region of

urban-rural

PREV_RXOUD_ED

OUD

(uniform)

Code

Rural Code

Event

hospital

hospital

designation

Hospital

1.000

.012

.008

-.032

-.384

-.005

-.402

-.100

-.219

.012

1.000

-.211

.027

.018

.005

.056

.112

.010

.008

-.211

1.000

.018

.014

-.018

-.010

-.015

-.016

-.032

.027

.018

1.000

-.152

.002

-.071

-.070

-.109

-.384

.018

.014

-.152

1.000

-.004

.325

.005

.355

Type of ED Event

-.005

.005

-.018

.002

-.004

1.000

-.009

-.039

-.002

Control/ownership of

-.402

.056

-.010

-.071

.325

-.009

1.000

.333

.116

Region of hospital

-.100

.112

-.015

-.070

.005

-.039

.333

1.000

.185

Hospital urban-rural

-.219

.010

-.016

-.109

.355

-.002

.116

.185

1.000

PREV_RXOUD_ED
String to numeric recode
of OUD
Primary expected payer
(uniform)
Median household
income national quartile
for patient ZIP Code
Patient Location: NCHS
Urban-Rural Code

hospital

designation
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Sig. (1-tailed)

Log Transformation of

.

.000

.000

.000

.000

.000

.000

.000

.000

.000

.

.000

.000

.000

.000

.000

.000

.000

.000

.000

.

.000

.000

.000

.000

.000

.000

.000

.000

.000

.

.000

.058

.000

.000

.000

.000

.000

.000

.000

.

.000

.000

.000

.000

Type of ED Event

.000

.000

.000

.058

.000

.

.000

.000

.090

Control/ownership of

.000

.000

.000

.000

.000

.000

.

.000

.000

Region of hospital

.000

.000

.000

.000

.000

.000

.000

.

.000

Hospital urban-rural

.000

.000

.000

.000

.000

.090

.000

.000

.

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

734627

outcome variable
PREV_RXOUD_ED
String to numeric recode
of OUD
Primary expected payer
(uniform)
Median household
income national quartile
for patient ZIP Code
Patient Location: NCHS
Urban-Rural Code

hospital

designation
N

Log Transformation of
outcome variable
PREV_RXOUD_ED
String to numeric recode
of OUD
Primary expected payer
(uniform)
Median household
income national quartile
for patient ZIP Code
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Patient Location: NCHS

734627

734627

734627

734627

734627

734627

734627

734627

734627

Type of ED Event

734627

734627

734627

734627

734627

734627

734627

734627

734627

Control/ownership of

734627

734627

734627

734627

734627

734627

734627

734627

734627

Region of hospital

734627

734627

734627

734627

734627

734627

734627

734627

734627

Hospital urban-rural

734627

734627

734627

734627

734627

734627

734627

734627

734627

Urban-Rural Code

hospital

designation
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Variables Entered/Removeda
Model
1

Variables Entered
Type of ED Event, Median household income national quartile for patient ZIP Code, Primary expected payer (uniform),
Patient Location: NCHS Urban-Rural Code, String to numeric recode of

2

Variables Removed

Method
. Enter

OUDb

Region of hospital, Hospital urban-rural designation, Control/ownership of hospitalb

. Enter

a. Dependent Variable: Log Transformation of outcome variable PREV_RXOUD_ED
b. All requested variables entered.
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Model Summaryc
Std. Error of the
Model

R

R Square

Adjusted R Square

Estimate

Change Statistics
R Square Change

F Change

df1

df2

Sig. F Change

1

.396a

.156

.156

.30314

.156

27245.686

5

734621

.000

2

.504b

.254

.254

.28512

.097

31937.906

3

734618

.000

a. Predictors: (Constant), Type of ED Event, Median household income national quartile for patient ZIP Code, Primary expected payer (uniform), Patient Location: NCHS
Urban-Rural Code, String to numeric recode of OUD
b. Predictors: (Constant), Type of ED Event, Median household income national quartile for patient ZIP Code, Primary expected payer (uniform), Patient Location: NCHS
Urban-Rural Code, String to numeric recode of OUD, Region of hospital, Hospital urban-rural designation, Control/ownership of hospital
c. Dependent Variable: Log Transformation of outcome variable PREV_RXOUD_ED

111

ANOVAa
Model
1

2

Sum of Squares

df

Mean Square

F

Regression

12518.475

5

2503.695

Residual

67506.731

734621

.092

Total

80025.206

734626

Regression

20307.279

8

2538.410

Residual

59717.927

734618

.081

Total

80025.206

734626

Sig.
27245.686

.000b

31226.166

.000c

a. Dependent Variable: Log Transformation of outcome variable PREV_RXOUD_ED
b. Predictors: (Constant), Type of ED Event, Median household income national quartile for patient ZIP Code, Primary expected payer (uniform), Patient Location: NCHS
Urban-Rural Code, String to numeric recode of OUD
c. Predictors: (Constant), Type of ED Event, Median household income national quartile for patient ZIP Code, Primary expected payer (uniform), Patient Location: NCHS
Urban-Rural Code, String to numeric recode of OUD, Region of hospital, Hospital urban-rural designation, Control/ownership of hospital
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Coefficientsa

Model
1

Unstandardized

Standardized

95.0% Confidence Interval for

Coefficients

Coefficients

B

B
(Constant)
String to numeric recode

Std. Error

-2.450

.001

.017

.001

.006

Beta

t

Sig.

Correlations

Lower Bound

Upper Bound

Zero-order

Partial

Collinearity Statistics
Part

Tolerance

VIF

-1781.271

.000

-2.453

-2.447

.026

23.976

.000

.016

.019

.012

.028

.026

.954

1.048

.000

.021

19.217

.000

.005

.007

.008

.022

.021

.954

1.048

-.028

.000

-.094

-86.365

.000

-.028

-.027

-.032

-.100

-.093

.975

1.025

-.092

.000

-.399

-367.481

.000

-.093

-.092

-.384

-.394

-.394

.976

1.025

.000

.000

-.006

-5.431

.000

.000

.000

-.005

-.006

-.006

1.000

1.000

-2.443

.002

-1596.472

.000

-2.446

-2.440

.027

.001

.040

38.940

.000

.026

.028

.012

.045

.039

.941

1.063

.005

.000

.018

17.052

.000

.004

.006

.008

.020

.017

.953

1.049

-.031

.000

-.106

-103.329

.000

-.032

-.031

-.032

-.120

-.104

.968

1.033

-.060

.000

-.259

-223.479

.000

-.061

-.060

-.384

-.252

-.225

.754

1.326

.000

.000

-.008

-7.588

.000

-.001

.000

-.005

-.009

-.008

.998

1.002

of OUD
Primary expected payer
(uniform)
Median household
income national quartile
for patient ZIP Code
Patient Location: NCHS
Urban-Rural Code
Type of ED Event
2

(Constant)
String to numeric recode
of OUD
Primary expected payer
(uniform)
Median household
income national quartile
for patient ZIP Code
Patient Location: NCHS
Urban-Rural Code
Type of ED Event
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Control/ownership of

-.096

.000

-.320

-280.735

.000

-.096

-.095

-.402

-.311

-.283

.780

1.282

.005

.000

.016

14.066

.000

.004

.005

-.100

.016

.014

.826

1.211

-.023

.000

-.105

-94.775

.000

-.024

-.023

-.219

-.110

-.096

.833

1.201

hospital
Region of hospital
Hospital urban-rural
designation
a. Dependent Variable: Log Transformation of outcome variable PREV_RXOUD_ED
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Excluded Variablesa
Collinearity Statistics
Minimum
Model
1

Beta In

t

Sig.

Partial Correlation

Tolerance

VIF

Tolerance

Control/ownership of hospital

-.315b

-292.825

.000

-.323

.891

1.122

.877

Region of hospital

-.109b

-101.718

.000

-.118

.981

1.020

.941

Hospital urban-rural designation

-.101b

-88.292

.000

-.102

.870

1.149

.860

a. Dependent Variable: Log Transformation of outcome variable PREV_RXOUD_ED
b. Predictors in the Model: (Constant), Type of ED Event, Median household income national quartile for patient ZIP Code, Primary expected payer (uniform),
Patient Location: NCHS Urban-Rural Code, String to numeric recode of OUD
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Collinearity Diagnosticsa
Variance Proportions
Median
household

Condition
Model Dimension
1

2

Eigenvalue

Index

(Constant)

income

Patient

String to

Primary

national

Location:

numeric

expected

quartile for

NCHS

recode of

payer

patient ZIP

Urban-Rural

Type of ED

Control/ownership

Region of

urban-rural

OUD

(uniform)

Code

Code

Event

of hospital

hospital

designation

Hospital

1

4.190

1.000

.00

.02

.01

.01

.01

.01

2

.883

2.178

.00

.00

.00

.00

.00

.99

3

.433

3.111

.00

.76

.08

.01

.02

.00

4

.266

3.968

.00

.00

.02

.24

.60

.00

5

.178

4.852

.00

.10

.56

.39

.12

.00

6

.050

9.131

.99

.12

.34

.35

.25

.01

1

5.924

1.000

.00

.01

.00

.00

.00

.00

.01

.00

.01

2

.909

2.552

.00

.00

.00

.00

.00

.88

.07

.00

.00

3

.769

2.775

.00

.01

.01

.01

.00

.11

.64

.00

.00

4

.454

3.614

.00

.63

.02

.00

.02

.00

.01

.00

.15

5

.380

3.948

.00

.13

.09

.08

.02

.00

.04

.00

.42

6

.205

5.370

.00

.03

.05

.07

.51

.00

.02

.13

.20

7

.184

5.676

.00

.03

.29

.53

.07

.00

.01

.10

.00

8

.138

6.549

.01

.12

.34

.03

.17

.00

.15

.44

.23

9

.037

12.632

.99

.05

.20

.27

.21

.01

.06

.32

.00

a. Dependent Variable: Log Transformation of outcome variable PREV_RXOUD_ED
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Residuals Statisticsa
Minimum
Predicted Value

Maximum

Mean

Std. Deviation

N

-3.4049

-2.4827

-2.7140

.16626

734627

-4.156

1.391

.000

1.000

734627

.000

.006

.001

.000

734627

-3.4048

-2.4827

-2.7140

.16626

734627

-2.12295

1.11190

.00000

.28511

734627

Std. Residual

-7.446

3.900

.000

1.000

734627

Stud. Residual

-7.446

3.900

.000

1.000

734627

-2.12298

1.11193

.00000

.28512

734627

-7.446

3.900

.000

1.000

734627

Mahal. Distance

1.135

332.138

8.000

17.795

734627

Cook's Distance

.000

.001

.000

.000

734627

Centered Leverage Value

.000

.000

.000

.000

734627

Std. Predicted Value
Standard Error of Predicted
Value
Adjusted Predicted Value
Residual

Deleted Residual
Stud. Deleted Residual

a. Dependent Variable: Log Transformation of outcome variable PREV_RXOUD_ED
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118

119

120
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